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ABSTRACT 
Despite widespread use of the Bacille Calmette-Guérin (BCG) vaccine, tuberculosis (TB) remains a 
leading cause of global mortality from a single infectious agent (Mycobacterium tuberculosis or Mtb). 
Here, over two independent Mtb challenge studies, we demonstrate that subcutaneous vaccination of 
rhesus macaques (RM) with Rhesus Cytomegalovirus vectors encoding Mtb antigen (Ag) inserts 
(RhCMV/TB), which elicit and maintain highly effector-differentiated, circulating and tissue-resident 
Mtb-specific CD4+ and CD8+ memory T cell responses, can reduce the overall (pulmonary and extra-
pulmonary) extent of Mtb infection and disease by 68% compared to unvaccinated controls after intra-
bronchial Erdman strain Mtb challenge, with challenge occurring at ~1 year after first vaccination. 
Fourteen of 34 RhCMV/TB-vaccinated RM (41%) across both studies showed no TB disease by CT scan 
or at necropsy after challenge (compared with 0 of 17 unvaccinated controls) and 10 of these RM were 
Mtb culture-negative in all tissues, an exceptional long-term vaccine effect in the Erdman strain Mtb RM 
challenge model. These results suggest that complete vaccine-mediated immune control of highly 
pathogenic Mtb is possible if immune effector responses can intercept Mtb infection at its earliest stages. 
 
INTRODUCTION 
The natural immune response to Mycobacterium tuberculosis (Mtb), characterized pathologically by 
necrotizing granulomatous inflammation, limits the progression of infection in most subjects, but at the 
same time provides a haven for pathogen persistence and promotes host-to-host transmission1-4. An 
emerging consensus in the field suggests that over many thousands of years of evolution as an obligate 
human pathogen, Mtb has developed the ability to manipulate the human immune response so as to 
achieve the optimal balance between pathogenicity and immunity that provides maximal penetrance in the 
human population1,2,5-7. Natural Mtb immunity would therefore include a mixture of protective and anti-
protective components, the latter of which would contribute to Mtb persistence and transmission. In 
keeping with this hypothesis, the Mycobacterium bovis-derived BCG vaccine, which enhances natural 
adaptive anti-mycobacterial immunity, is not completely efficacious. BCG protects vaccinated 
individuals, particularly children, from severe miliary TB, but fails to substantially reduce the incidence 
of pulmonary TB in adolescents and adults, a requirement for vaccine-mediated control of the global TB 
epidemic4,8,9. A corollary of this hypothesis is that for a vaccine to have sufficient potency to prevent 
pulmonary TB and thereby impact the TB epidemic, it will likely need to possess the following 
characteristics: 1) the ability to elicit effective, durable anti-Mtb immune responses that lack the 
components of natural Mtb immunity that are advantageous to the microbe, and 2) the ability to 
control/eliminate any nascent Mtb infection prior to the microbe’s establishment of an immune 
environment conducive to persistence (likely including mature granulomas), and/or be potent enough to 
overcome any Mtb-associated immunoregulation contributing to persistence. Studies in the mouse TB 
model have shown that accelerating effector cell production and delivery to lung in primary Mtb infection 
improves outcome10. Consistent with this concept of enhanced Mtb control with earlier effector cell 
delivery, vaccination of nonhuman primates (NHP) via aerosol delivery of either BCG or an attenuated 
Mtb vaccine, which potentiates both innate and adaptive cellular immune responses in the lung, has been 
shown to enhance protection against Mtb challenge11-13. Heterologous viral vaccine vectors would 
presumably have advantages over mycobacteria-based vaccines as these agents would likely lack the anti-
protective immunoregulatory manipulation of mycobacteria, yet would potentially have an ability to elicit 
Mtb-specific CD4+ and CD8+ T cell responses with relevant functional profiles (for example, the ability to 
synthesize effector cytokines such as IFN-g and TNF which are associated with Mtb control1,2,9). To date, 
however, TB vaccines based on poxvirus and adenovirus vectors have shown only modest enhancement 
of Mtb control in NHP models, and a Phase 2b trial of a Modified Vaccinia Ankara/Ag85A vaccine failed 
to show clinical benefit14-18. 
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The reason for the limited success of poxvirus- and adenovirus-based vectors as TB vaccines is unknown, 
but we hypothesize that these particular viral vectors simply failed to elicit, maintain and/or deliver 
sufficient numbers of functionally appropriate, effector-differentiated, Mtb-specific T cells at relevant 
tissue sites such as the bronchial mucosa, alveolar tissue and lung-draining lymph nodes (LNs) to 
effectively control Mtb challenge. In this regard, we and others have previously shown that 
Cytomegalovirus (CMV) is unique among microbial agents that infect humans and NHP in its ability to 
elicit and maintain robust, life-long, circulating and tissue-resident, effector-differentiated CD4+ and CD8+ 
memory T cell responses19,20. Indeed, CMV-specific CD4+ and CD8+ T cells constitute an average of 10% 
of the entire circulating memory T cell population in CMV-infected people21. We also have previously 
demonstrated that RhCMV-based vectors can be exploited as a uniquely effective “effector memory” 
vaccine against simian immunodeficiency virus (SIV) in RM22-24, and have established that these vectors 
can elicit and maintain circulating and tissue-resident CD4+ and CD8+ effector-differentiated T cells 
(transitional effector memory T cells – TTrEM and fully differentiated effector memory T cells – TEM) to 
any exogenous Ag insert22-25, including those encoding Mtb proteins25. Since RhCMV vector-elicited 
TTrEM/TEM both circulate in blood and accumulate in lung, and can produce copious amounts of TNF and 
IFN-g upon Ag recognition22-24, the RhCMV/TB vaccine provides a unique opportunity to experimentally 
test the hypothesis that such high frequency, preformed, in situ or rapidly recruited, Mtb-specific TNF- 
and IFN-g-producing TTrEM/TEM would be able to abrogate or markedly reduce TB progression after highly 
pathogenic Mtb challenge.  
 
RESULTS 
Relative Immunogenicity of RhCMV/TB and BCG (Study 1) 
RM are highly susceptible to Mtb infection (particularly the highly pathogenic Erdman strain), even with 
very low doses of challenge inoculum, and show very similar immunology and pathology to humans, with 
the exception that whereas most (~85-90%) human TB infections are non-progressive over the lifetime of 
the infected individual, the vast majority of Mtb-infected RM progress to disease following experimental 
exposure4,26-30. Mtb infection of RM therefore represents a close-to-human, yet extremely stringent, model 
for testing TB vaccine activity. Indeed, the protection afforded by intradermally administered (i.d.) BCG 
vaccine in this model is variable and modest8,13,16,31, allowing vaccine developers to target enhancement of 
protection over that of i.d. BCG in this model as the goal of any new TB vaccine concept.  
To test the hypothesis that vaccination with RhCMV/TB would elicit more effective immunity than i.d. 
BCG, and/or enhance the protection of i.d. BCG vaccination, we vaccinated 3 groups of RM (n=7/group; 
all naturally RhCMV+ at study assignment) with the following vaccines: 1) RhCMV/TB alone 
(subcutaneous administration of a set of 4 RhCMV vectors based on the 68-1 strain that together express 
9 different Mtb proteins: ESAT-6, Ag85A, Ag85B, Rv3407, Rv1733, Rv2626, Rpf A, Rpf C, Rpf D; 
Supplementary Fig. 1a), 2) i.d. BCG alone, and 3) i.d. BCG followed (6 weeks later) by subcutaneous 
RhCMV/TB vaccination (Fig. 1a). As expected, the RhCMV/TB vaccine elicited and maintained high 
frequency CD4+ and CD8+ T cell responses in blood to all 9 Mtb inserts, as measured by overlapping 
15mer peptide mix-induced expression of intracellular TNF and/or IFN-g by flow cytometric intracellular 
cytokine (ICS) analysis (Fig. 1b-c). During the plateau phase, RhCMV vector-elicited Ag85A-specific 
responses were predominantly effector-differentiated, manifesting an almost exclusive TEM phenotype for 
CD8+ T cell responses, and a mixed TTrEM and TEM phenotype for CD4+ T cell responses (Fig. 1d). 
Approximately half of the RhCMV/TB-elicited Ag85A-specific CD4+ and CD8+ T cells responding in the 
ICS assays produced both TNF and IFN-g (with or without IL-2), with the remainder predominantly 
producing TNF alone (Fig. 1e). BCG induced circulating CD4+ and CD8+ T cell responses to 8 of the 9 
insert Ags (all except ESAT-6, which is not expressed by BCG32). In peripheral blood, the overall 
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magnitude of the BCG-elicited T cell responses to these 8 Ags was considerably less than observed in 
RhCMV/TB-vaccinated RM (Fig. 1b,c). BCG-elicited Ag85A-specific responses predominantly 
exhibited a central memory (TCM) phenotype for the CD4+ T cells, and a TEM phenotype for the CD8+ T 
cells (Fig. 1d).  The majority of these Ag85A-specific T cells produced either TNF or IL-2 alone (CD4+) 
or TNF or IFN-g alone (CD8+), but not both TNF and IFN-g (Fig. 1e). Notably, the BCG-induced CD4+ 
and CD8+ T cell response to the 8 BCG-expressed Mtb Ags was not large enough to significantly change 
the plateau-phase magnitude, phenotype, or function of the peripheral blood Mtb Ag-specific responses in 
the RM that received both BCG and RhCMV/TB relative to the RM that received RhCMV/TB 
vaccination alone (Fig. 1b-e). Differences in response magnitude between BCG- and RhCMV/TB-
vaccinated RM were less apparent in bronchoalveolar lavage (BAL) fluid, with the responses in the latter 
group only modestly higher than in the former group (Fig. 1f). None of the 3 vaccinations used in Study 1 
elicited significant antibody (Ab) responses to the 9 TB Ags in the RhCMV vector inserts 
(Supplementary Fig. 1b). 
Effect of BCG, RhCMV/TB, and BCG + RhCMV/TB vaccination on Mtb challenge (Study 1) 
Fifty weeks after initial vaccination, the 3 groups of vaccinated RM and a control group of unvaccinated 
RM (n=8; all naturally RhCMV+) were challenged by intrabronchial instillation of 25 colony-forming 
units (CFUs) of Erdman strain Mtb bacteria into the right lower lobe. The effectiveness of challenge was 
confirmed by de novo development of CD4+ and CD8+ T cell responses to the CFP-10 Ag (Fig. 2a, 
Supplementary Fig. 2a; note that the Mtb-expressed CFP-10 Ag was not included in the RhCMV/TB 
vectors, and, like ESAT-6, is not expressed by BCG32). The unvaccinated RM manifested de novo CD4+ 
and CD8+ T cell responses to all 9 TB vaccine-insert Ags, including strong responses to ESAT-6 (Fig. 2b; 
Supplementary Fig. 2b). Only a very modest increase in the magnitude of CD4+ and CD8+ T cell 
responses to the TB vaccine-insert Ags was detected after Mtb challenge in vaccinated RM from all 3 
vaccine groups (shown as the change in %responding from baseline; Fig. 2b; Supplementary Fig. 2b). 
The observation that the magnitude of this change-from-baseline after challenge in the vaccinated RM 
was not significantly different from the magnitude of the de novo responses to challenge in unvaccinated 
RM suggests that none of the vaccines used in this study were able to prime for an anamnestic Mtb-
specific T cell response (i.e., a secondary, systemic immune response of substantially greater magnitude 
than the primary response). Initially, we planned to monitor post-challenge pulmonary immune responses 
by BAL, but BAL was discontinued when 2 RM were taken to necropsy due to acute cardiopulmonary 
complications associated with the BAL procedure (see Methods). The development of pulmonary disease 
after challenge was monitored every two weeks by CT scan assessment of lesion volume, and both 
pulmonary and extra-pulmonary disease was determined at necropsy, with necropsy targeted to be 
performed either at clinical endpoint, or after 20 weeks post-infection (pi), by randomization (Fig. 1a). 
The extent of Mtb infection and TB disease at necropsy was quantified by 1) detailed pathologic scoring 
(based on comprehensive gross and microscopic pathologic examination; see Supplementary Fig. 3 and 
Methods), 2) by the frequency of recovery of culturable Mtb from a standard set of tissue samples, 
including 40 lung punch biopsies (randomly sampled using stereology to standardize sample collection 
across all study RM), as well as representative samples of trachea, all lung-draining and other chest LNs 
(hilar, carinal, paratracheal, mediastinal), selected peripheral LNs (axillary, inguinal, mesenteric) and 
other selected organs (spleen, liver, kidney, pancreas), and 3) by the amount of culturable Mtb in lung-
draining LNs (CFU/gm), a nearly universal site of Mtb infection in RM with progressive TB disease26. 
Pulmonary disease developed rapidly in unvaccinated control RM with progression to severe (≥10,000 
mm3) lung parenchymal disease by CT scan in 7 of 8 RM by day 56pi and all RM by day 98pi (Fig. 2c).  
In both RM groups that received i.d. BCG, the development of pulmonary disease was more variable, but 
5 of 7 RM in each group developed severe disease by day 98pi. In contrast, 5 of the 7 RM vaccinated with 
RhCMV/TB-alone developed only mild pulmonary disease (<3,000 mm3, n=4) or no disease (n=1). The 
overall area-under-the-curve (AUC) of pulmonary lesion volume of the RhCMV/TB-alone group during 
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the first 16 weeks pi (using imputed AUC values for monkeys taken to necropsy prior to week 16 pi, see 
Methods) was significantly reduced compared with the unvaccinated control group (Fig. 2d; 
Supplementary Fig. 4a), whereas there was no significant reduction in this parameter in either the i.d. 
BCG-alone or i.d. BCG + RhCMV/TB groups. Across all groups, the CT-determined lesional AUC 
through week 16 closely correlated with pulmonary parenchymal disease at necropsy as measured by both 
pathologic scoring and extent of Mtb recovery by culture (Supplementary Fig. 5a), and consistent with 
this, the extent of pulmonary TB at necropsy was also significantly reduced in the RhCMV/TB vector 
group compared to unvaccinated controls by both these necropsy measures (Fig. 2e; Supplementary Fig. 
4a). No significant pulmonary disease reduction was observed in the i.d. BCG-only vaccinated cohort by 
either necropsy measure, and the combination i.d. BCG + RhCMV/TB vaccine regimen resulted in a 
significant reduction in Mtb burden, but not in pathologic score.  
TB is typically not restricted to pulmonary parenchyma in RM infected with Erdman strain Mtb26, and 
necropsy analysis revealed extensive extra-pulmonary disease in the unvaccinated RM, including both 
lung-associated LN involvement and extra-thoracic spread (Supplementary Fig. 6). Importantly, the 
extent of overall disease as measured by pathologic score was also closely correlated with the recovery of 
viable Mtb in pulmonary and non-pulmonary parenchymal tissues (Supplementary Fig. 5b), and by both 
pathologic and Mtb recovery criteria, extra-pulmonary and overall disease was significantly reduced in the 
RhCMV/TB-vaccinated cohort relative to unvaccinated RM (Fig. 2f,g; Supplementary Fig. 4a). We also 
found a >2 log reduction in the density of culturable Mtb (CFU/gm) in all lung-draining LNs in 
RhCMV/TB-vaccinated RM compared to unvaccinated control RM (P=0.0003; Supplementary Fig. 5e). 
By Poisson modeling, the overall (pulmonary + extra-pulmonary) extent of disease was reduced in the 
RhCMV/TB-vaccinated group by 68.7% by extent of Mtb recovery (P<0.0001) and 67.3% by pathologic 
score (P<0.0001) relative to unvaccinated controls (Supplementary Fig. 4b). In contrast, the extent of 
extra-pulmonary and overall disease in i.d. BCG-only vaccinated RM was not significantly different from 
unvaccinated RM by either criterion (Fig. 2f,g; Supplementary Fig. 4a). The density of viable 
mycobacteria in lung-draining LNs was also not different in i.d. BCG-vaccinated RM relative to 
unvaccinated controls (Supplementary Fig. 5e). In keeping with these results, the extent of extra-
pulmonary and overall disease, as well as the density of viable Mtb in lung-draining LNs, in RM receiving 
RhCMV/TB alone, was also significantly reduced when directly compared to the i.d. BCG-only 
vaccinated RM (Fig. 2f,g; Supplementary Figs. 4a and 5e). Using the same Poisson modeling, 
RhCMV/TB vaccination reduced overall disease relative to i.d. BCG vaccination alone by 57.7% 
(P=0.0007) and 51.4% (P=0.01) for extent of Mtb recovery and pathologic score, respectively (Supple-
mentary Fig. 4b). Vaccination of RM with i.d. BCG 6 weeks before the initial RhCMV/TB vaccination 
appeared to reduce both the pulmonary and extra-pulmonary protection mediated by the RhCMV/TB 
vaccination alone, as the i.d. BCG + RhCMV/TB group did not manifest a significant reduction in 
pathologic score relative to unvaccinated controls. However, the extent of Mtb recovery in both 
pulmonary and extra-pulmonary tissues and the density of viable Mtb in lung-draining LNs was still 
significantly reduced in the RM receiving i.d. BCG + RhCMV/TB relative to unvaccinated controls (Fig. 
2e-g; Supplementary Figs. 4a and 5e). Thus, RhCMV/TB-vaccinated RM manifested superior overall 
outcomes compared to RM vaccinated with i.d. BCG alone, and the i.d. administration of BCG 6 weeks 
prior to RhCMV/TB vaccination appeared to reduce, but not abolish, the protection afforded by the 
RhCMV/TB vaccine.  
Immunogenicity and protective capacity of RhCMV/TB variants (Study 2) 
To confirm and further characterize the protective effect of RhCMV/TB vaccination, we performed a 
second larger Mtb challenge study (n=9/group; all RM naturally RhCMV+ at assignment) in which we 
compared the same 68-1 RhCMV/TB-9 Ag vector set used in Study 1 (group 1) with an analogous 
RhCMV/TB-9 Ag vector set based on the 68-1.2 RhCMV backbone (group 2), and with a 68-1 
RhCMV/TB-6 Ag vector expressing a single 6 Ag Mtb polyprotein (Ag85A; ESAT-6; Rv3407; Rv2626; 
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Rpf A; Rpf D) (group 3) (Fig. 3a; Supplementary Fig. 1). Strain 68-1 RhCMV vectors elicit 
unconventional CD8+ T cell responses that are restricted by MHC-II and MHC-E, whereas the 
Rh157.5/Rh157.4-repaired 68-1.2 RhCMV vectors elicit CD8+ T cells that target conventionally MHC-Ia-
restricted epitopes25,33. The comparison of group 1 to group 2 therefore allows determination of the 
contribution of unconventionally restricted CD8+ T cells to RhCMV/TB-mediated protection. In the group 
1 vs. group 3 comparison, we sought to determine whether the vaccine effect observed in Study 1 with the 
4 RhCMV/TB vector set encoding 9 Mtb Ags (3 each in the acute phase, latency and resuscitation Ag 
types) can be recapitulated by a single RhCMV/TB vector expressing 6 Mtb Ags (2 each from these Ag 
types) as a single polyprotein, a simpler vaccine configuration which is better suited for clinical 
translation. As expected, the magnitude of the overall Mtb-specific and individual Mtb insert-specific 
CD4+ and CD8+ T cell responses elicited by the 68-1 and 68-1.2 RhCMV/TB-9 Ag vectors were 
comparable in blood throughout the vaccination phase, and in BAL and peripheral LN at the end of 
vaccination phase, as was the memory differentiation and functional phenotype of the Mtb-specific 
response in blood (Fig. 3b-g). However, also as expected25, the CD8+ T cells elicited by the 68-1 
RhCMV/TB vaccine were unconventionally (MHC-II and MHC-E) restricted, whereas those elicited by 
68-1.2 RhCMV/TB vaccine were conventionally (MHC-Ia) restricted (Supplementary Fig. 7). The T cell 
responses recognizing the 6 Ags common to both the 68-1 RhCMV/TB-6 Ag and RhCMV/TB-9 Ag 
vaccines were similar between groups 1 and 3 with respect to magnitude, phenotype and (unconventional) 
MHC restriction, except for slightly different levels of CD8+ T cell responses in peripheral LN (Fig. 3b-g; 
Supplementary Fig. 7). Thus, the 3 different RhCMV-based vaccines used in Study 2 generated CD4+ 
and CD8+ T cell responses to insert Ags that were of comparable magnitude, function and phenotype, but 
differed, as intended, in the epitope targeting and restriction of the CD8+ T cell responses (68-1 vs. 68-
1.2), or in the number of Mtb Ags targeted (6 Ag vector vs. 9 Ag vector sets). As in Study 1, none of the 3 
RhCMV/TB vaccines used in Study 2 elicited a specific Ab response to any of the 9 TB Ags expressed by 
these vectors (Supplementary Fig. 1b). 
After a 56-week vaccination period, all vaccinated RM (groups 1-3) and unvaccinated control RM (group 
4) were intrabronchially challenged with ~10 CFUs of Erdman strain Mtb bacteria – the reduction in dose 
relative to Study 1 was intended to slow TB progression in Study 2 RM to more closely resemble the 
course of human Mtb infection. In addition, BAL was not performed post-challenge in this experiment to 
prevent procedure-related mortality and the possibility of artificial enhancement of bacteria spread within 
the lung. All Study 2 RM developed de novo CFP-10-specific T cell responses in blood following 
challenge, and the RhCMV/TB-6 Ag-vaccinated RM (group 3) also developed de novo T cell responses in 
blood to the Ag85B, Rpf C, and Rv1733 Ags, which were not included in their vaccine (Fig. 4a,b; 
Supplementary Fig. 2c,d). As observed in Study 1, the change-from-baseline in the magnitude of the 
post-challenge TB insert-specific CD4+ and CD8+ T cell responses in RhCMV/TB-vaccinated RM was 
less than or equal to the magnitude of the de novo responses to these Ags in the unvaccinated RM, 
confirming lack of a true anamnestic response in the RhCMV/TB-vaccinated animals (Fig. 4c; Supple-
mentary Fig. 2e). All 9 unvaccinated (group 4) RM developed TB lesions on CT scans by day 28pi, but 
as anticipated, the disease progression in this study was slower and reached a lower plateau earlier than in 
Study 1 (Fig. 4d), with only 2 unvaccinated (group 4) control RM developing endpoint TB disease over 
the course of observation (Fig. 3a). Remarkably, 13 of the 27 vaccinated RM (5 RM each in group 1 and 
group 3 and 3 RM in group 2) did not develop any radiologic signs of pulmonary TB (including no CT-
detectable hilar adenopathy) at any time point through to random elective necropsy at >16 weeks pi, and 
the average CT-determined lesional AUC in lung parenchyma of the overall cohort of vaccinated RM was 
significantly reduced compared to the unvaccinated group 4 (Fig. 4d,e; Supplementary Fig. 4c).  
At necropsy, none of the 13 CT-negative RM from vaccine groups 1-3 had any macroscopic 
granulomatous disease, and 10 of these 13 were culture-negative in all tissue samples (the remaining 3 
were Mtb+ in lung-draining LNs only; Supplementary Figs. 5c,d and 9). Moreover, despite the 
development of CD4+ and CD8+ T cell responses to Mtb proteins not present within their vaccine in lung, 
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lung-draining and peripheral LNs, and spleen (Supplementary Fig. 8), extensive histopathologic analysis 
of lung and lung-draining LNs from these 13 TB disease-free RM showed no microscopic granulomatous 
inflammation. As in Study 1, the pathologic scores at necropsy (same as Study 1) and the extent of Mtb 
recovery (same as Study 1 except for expansion of analysis to retropharyngeal, submandibular, iliosacral 
LNs and tonsils) were again strongly correlated (Supplementary Fig. 5d). The overall extent of disease 
by both measures was significantly reduced in the overall (pooled groups 1-3) RhCMV/TB-vaccinated 
group compared to the unvaccinated control group, with no significant difference in protection between 
individual groups 1-3, and similar protection in both pulmonary and extra-pulmonary tissues (Fig. 4f-h; 
Supplementary Figs. 4c and 9). For the pooled vaccinated group, the overall reduction in disease extent 
relative to the unvaccinated control group was 74.5% by Mtb culture (P=0.0024) and 61.4% by pathologic 
score (P=0.0011) using Poisson modeling (Supplementary Fig. 4d).  
To assess the effect of RhCMV/TB vaccination (given alone) on Mtb challenge outcome, relative to no 
vaccination across Study 1 and Study 2, we used a scaled (normalized) combination outcome parameter 
based on both Mtb culture and pathologic score (see Methods). As shown in Fig. 4i, the difference in 
overall (Study 1 + 2) outcome between unvaccinated and RhCMV/TB (only)-vaccinated RM was highly 
significant, corresponding to a 68% reduction in this combined measure of Mtb infection and disease in 
the vaccinated RM by Poisson modeling (Supplementary Fig. 4e). Of note, despite the fact that the 
average extent of TB progression in the unvaccinated control RM was quite different in Studies 1 and 2, 
the relative reduction in infection and disease associated with RhCMV/TB vaccination was similar for 
each study (Supplementary Fig. 4). Across both Study 1 and 2, 14 of 34 RhCMV/TB (only)-vaccinated 
RM (41%; 95% confidence interval: 26%-58%) manifested no detectable granulomatous disease at 
necropsy (vs. 0 of 17 unvaccinated controls; P=0.0018), and 10 of these 14 were culture-negative for Mtb 
(Fig. 4j; Supplementary Figs. 6 and 9). Importantly, the extent of disease in the remaining RhCMV/TB 
(only) vaccinees (e.g., excluding the RhCMV/TB vaccinated RM with complete control and including 
only those vaccinated RM with detectable disease at necropsy; n = 20) was still significantly reduced 
compared with the unvaccinated controls (41.5% reduction by Poisson modeling; Fig. 4j and 
Supplementary Fig. 4e), indicating that in contrast to the “all or none” protection of the RhCMV/SIV 
vaccine against SIV challenge23,24, the vaccine effect of the RhCMV/TB vaccine includes both complete 
and partial protection. Of note, 32 of the 34 RM vaccinated with RhCMV/TB alone (94%), manifested an 
extent of disease at necropsy less than the median in the unvaccinated controls, and 24 of the 34 
vaccinated RM (71%) manifested an extent of disease at or below the lowest level of disease extent in the 
unvaccinated controls (Fig. 4j). 
Innate response to Mtb challenge is modified in RhCMV/TB protected RM 
Development of active TB after Mtb infection in humans is associated with profound changes in the 
expression of immune-related and inflammatory genes in whole blood34-37. To determine whether our 
study RM manifested analogous transcriptional changes after Mtb challenge, and whether vaccine-
associated protection modified this signature, we performed RNA-sequencing (RNA-Seq) transcriptome 
analysis of whole blood RNA collected immediately prior to, and 28 days after Mtb challenge. We first 
determined whether genes that were significantly up- or down-regulated in active TB patients compared 
to controls in two African cohorts37 were similarly regulated in the blood of the unvaccinated RM after 
challenge. As shown in Fig. 5a,b, the unvaccinated control RM in our study displayed a whole blood 
transcriptional response to Mtb infection that was highly congruent with the response in humans, 
involving similar and robust up- and down-regulation of a common set of immune-associated modules 
and pathways. We next tested whether the magnitude of induction of this whole blood transcriptional 
signature at 28 days Mtb post-challenge was associated with outcome at necropsy across all Study 1 and 
Study 2 RM, as measured by the scaled combination outcome parameter described above. As shown in 
Fig. 5c-e, a large number of genes that were highly enriched for the interferon transcriptional module 
exhibited expression patterns that strongly correlated with extent of disease of Study 1 and 2 RM at 
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necropsy. These interferon response genes include members of a signature associated with progression to 
active TB disease in humans34, classical antiviral responses (e.g., IRF7, IFIH1, DDX58, RSAD2) and 
inflammasome components (AIM2 and STAT1). Notably, this TB disease-associated transcriptional 
signature was profoundly reduced in the vast majority of RhCMV/TB-vaccinated RM with complete Mtb 
control, indicating that in these RM, protective vaccine-elicited immune responses countered the spread of 
Mtb early enough after challenge to ameliorate the potent generalized effect of Mtb infection on innate 
immune signaling.    
Correlates of protection 
Given the effector memory nature of RhCMV/TB vaccine-elicited T cell responses, and the lack of 
anamnestic T cell or relevant Ab responses, the variable level of protection observed in RhCMV/TB 
vaccinated RM (ranging from complete to none) would likely reflect a composite integration of the 
frequency and function of RhCMV/TB vaccine-elicited T cells, as well as that of innate immune effectors, 
immediately after challenge, at the local sites of early Mtb replication in lung and lung-draining LNs. 
Since direct immunologic interrogation of all these sites is not possible, we asked whether analysis of 
accessible, surrogate sites would provide insight into the immunologic differences among RhCMV/TB 
vaccinated RM (with or without i.d. BCG) that determine subsequent control or non-control of Mtb 
challenge. In this regard, the outcome heterogeneity among all RhCMV/TB-vaccinated RM in Study 1 
and 2, as measured by the scaled combination outcome parameter described in Fig. 4, was not predicted 
by the ICS-determined magnitudes of the RhCMV/TB-elicited, TNF/IFN-g-defined, CD4+ and/or CD8+ T 
cell responses in blood or BAL (or Study 2 only, peripheral LN) immediately prior to challenge 
(Supplementary Fig. 10a-c). In addition, in Study 2, there were no significant differences in the AUC of 
the post-challenge Mtb Ag-specific CD4+ and CD8+ T cell response magnitudes between the 13 
RhCMV/TB-vaccinated RM that were completely protected after challenge and the 14 RhCMV/TB-
vaccinated RM with TB disease (Supplementary Fig. 10d,e), except for reduced ESAT-6- and CFP-10-
specific CD4+ T cell responses in the protected group (likely reflecting lower antigenic loads of these two 
related acute-phase Ags in the protected RM after challenge).  
These data suggest that the overall Mtb-specific T cell responses measured in these surrogate sites may 
not accurately reflect the relevant memory T cell responses in lung tissue and lung-draining LN and/or 
that the measured responses are not the only, or not the major, limiting immunologic factors that 
determine outcome. To more globally determine whether other peripheral readouts of immune and 
inflammatory state are associated with differential outcomes after Mtb challenge in RhCMV/TB-
vaccinated RM, we analyzed the pre-challenge whole blood transcriptomes to identify gene expression 
associations with the scaled combination outcome measure. This analysis revealed a set of 280 genes with 
pre-challenge expression profiles that were significantly associated with eventual outcome (p<0.05, 
FDR<0.33), out of which 258 (92%; Fig. 6a) exhibited no significant pre-challenge association with 
outcome for unvaccinated and i.d. BCG-vaccinated RM – suggesting that these signatures are associated 
with outcome only in the context of RhCMV/TB vaccination. Transcriptional module and pathway 
enrichment analysis revealed significant (p<0.05, FDR<0.15) over-representation of neutrophil 
degranulation and innate immunity functions amongst genes that were expressed higher in RM that would 
ultimately be protected (“protection signature”), whereas genes that were expressed higher in RM that 
would ultimately develop severe disease (“susceptibility signature”) were significantly enriched for the T 
cell transcriptional module (Fig. 6b,c). Although these enrichment analysis results raise the possibility 
that relative abundances of specific leukocyte populations prior to Mtb challenge would be associated 
with eventual outcome, no significant associations between outcome and leukocyte population counts 
were identified. Nevertheless, genes significantly correlated with neutrophil counts were over-represented 
within the protection signature, whereas genes significantly correlated with T cell counts (and to a lesser 
extent, monocytes) were over-represented within the susceptibility signature (Fig. 6a), consistent with the 
module and pathway analysis results. Visual inspection of the heatmap for the protection and 
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susceptibility signatures (Fig 6a) suggested that the association with protection was predominantly binary, 
with strongly protected RM exhibiting a distinct expression pattern compared to other RM. Logistic 
regression modeling of the data supported this interpretation, with 38/77 (49%) and 70/181 (39%) of 
protection and susceptibility genes, respectively, demonstrating reasonable potential to discriminate the 
14 protected RM from the remaining RhCMV/TB-vaccinated RM. Since the i.d. BCG + RhCMV/TB-
vaccinated group from Study 1 exhibited a trend towards impaired protection compared to the 
RhCMV/TB-only vaccinated group alone (despite having similar RhCMV/TB-elicited T cell responses; 
Fig. 1b-f), we assessed whether expression of the protection signature was impaired in Study 1 i.d. BCG 
+ RhCMV/TB RM compared to RhCMV/TB-only vaccinated RM on the day of challenge (Fig. 6d).  This 
analysis revealed that a subset of protection signature genes, including MMP8, CTSG, and CD52, were 
suppressed in the i.d. BCG + RhCMV/TB-vaccinated group relative to the RhCMV/TB-only vaccinated 
group, suggesting that BCG-driven modulation of inflammation may have countered a protective innate 
immune response in RhCMV/TB vaccinated RM, and thereby contributed to the reduced protection 
observed with the combined vaccine regimen.   
 
DISCUSSION 
In this report, we demonstrate that subcutaneously administered RhCMV-based TB vaccines are able to 
elicit and maintain immune effector responses that can control Mtb at the earliest stages of infection, and 
that the protection afforded by this vaccine can be complete, if not sterilizing. To our knowledge, this is 
the first demonstration of complete prevention of TB disease in a substantial fraction of RM by a 
peripherally administered, long-acting vaccine after highly pathogenic (Erdman strain) Mtb challenge. 
Although Kaushal, et al.12 have reported impressive protection in RM against a less pathogenic Mtb strain 
(CDC1551) with high dose, aerosol “vaccination” of a live, attenuated mycobacterium-based TB vaccine 
(MtbDSigH), in their studies, Mtb challenge occurred only 8 weeks after aerosol vaccine administration, a 
time when their replicating MtbDSigH would still be present in lungs of vaccinated RM and both innate 
and adaptive immunity would presumably be at or near peak levels. In contrast, the potent RhCMV/TB 
vaccine-mediated protection demonstrated here against low-dose, but highly pathogenic, Erdman strain 
Mtb challenge occurred as long as 55 weeks following initial vaccination, and 40 weeks following boost 
of the subcutaneously administered vaccine, consistent with establishment of long-term protection.  
The working hypothesis upon which CMV vaccine vector development is based relates to the ability of 
these persistent vectors to elicit and maintain effector-differentiated (“effector memory”), insert-specific 
CD4+ and CD8+ T cell responses in mucosal effector sites and secondary lymphoid tissues, as well as 
circulating in the blood, pre-positioned to intercept mucosally-acquired pathogens at the very onset of 
infection. While it is difficult to definitively establish mechanism-of-action in a vaccine protection study, 
the available data are consistent with the operation of this “effector memory” hypothesis in the 
RhCMV/TB vaccine-mediated control of Mtb infection. In keeping with previous work on RhCMV/SIV 
vaccines22-24, RhCMV/TB vectors elicit robust circulating and tissue-based CD4+ and CD8+ T cell 
responses (but little to no insert-specific Ab responses), with both the CD4+ and CD8+ T cell responses 
being highly effector memory-biased (TTREM + TEM for CD4+; TEM for CD8+). Although there are other 
semi-innate and innate cell types in the lung and lung-draining LNs that could potentially participate in 
protection against Mtb38, the effector-differentiated, Mtb-specific CD4+ and CD8+ T cells are essentially 
the only adaptive immune responses detected in RhCMV/TB-vaccinated RM. Moreover, protection 
appeared very early in many RM – before the onset of detectable pathology and early enough to reduce 
and even abrogate the potent interferon-driven innate immune response to Mtb infection. This protection 
also occurred in the absence of a true anamnestic response, consistent with the concept of protection being 
mediated by established effectors already “in place” or rapidly recruited at the time of challenge. It is also 
noteworthy that the most pronounced adaptive immune difference between RhCMV/TB-elicited and the 
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(non-protective) i.d. BCG-elicited T cell responses was in the Mtb-specific CD4+ T cell responses prior to 
challenge, in particular their differentiation and functional potential, with the i.d. BCG vaccine eliciting 
predominantly monofunctional, central memory responses vs. polyfunctional (TNF- + IFN-g-producing) 
effector-differentiated (TEM + TTREM) responses by the RhCMV/TB vaccine. With respect to Mtb-specific 
CD8+ T cell responses, the protection afforded by 68-1.2 RhCMV/TB vaccination indicates the 
unconventional MHC-II and MHC-E-restricted CD8+ T cells are not required for protection, and suggests 
that either conventional or unconventional CD8+ T cell responses can contribute to protection, or that 
protection is independent of CD8+ T cells altogether. 
The observation that outcome heterogeneity among RhCMV/TB vaccinated RM was not predicted by the 
pre-challenge magnitude of RhCMV/TB-elicited, TNF/IFN-g-defined, CD4+ or CD8+ T cell responses in 
blood, BAL or LN does not refute the “effector memory” hypothesis, as these sampling sites and the ICS 
assay read-out may not accurately reflect the frequency and function of resident memory responses in 
lung and lung-draining LN that are likely the relevant population for earliest immune control of infection 
and thus for protection39. In contrast to T cell responses that either continuously recirculate (central 
memory responses) or have a required blood-borne component (classic anamnestic memory responses), 
effector memory responses are regulated locally, are not well represented by blood measurements, are 
difficult to characterize ex vivo, and are not uniform across tissue compartments40,41. It should also be 
noted that a correlation between pre-challenge Mtb insert-specific T cell response magnitude and 
subsequent protection would be expected only if this T cell response magnitude was the major limiting 
component of the protective immune response. Since CD4+ and CD8+ T cells are not thought to directly 
kill Mtb, but rather to work through innate immune (primarily phagocytic) effectors, it is possible that a 
required innate immune co-effector component is the limiting factor that primarily determines whether an 
individual RhCMV/TB vaccinee will be completely protected, partially protected, or not at all protected 
after challenge. In this regard, the gene expression levels identified in pre-challenge transcriptomic 
analysis as predictive of the RhCMV/TB vaccine effect preferentially included genes expressed by 
neutrophils and associated with innate immunity and neutrophil degranulation gene pathways, including 
genes that encode neutrophil granule effector molecules (MMP8, CTSG) (Fig. 6). This protection 
signature is somewhat surprising since in overt TB disease, neutrophils have been primarily associated 
with TB pathogenesis, mediating tissue destruction, necrosis, and cavitation, and providing a pro-Mtb 
milieu, but not effective Mtb killing42-45. However, some studies have demonstrated an ability of 
neutrophils to kill, growth-restrict, or trap Mtb (preventing its spread), raising the question of whether the 
role of the neutrophil in TB immunity and pathogenesis is both timing and context dependent7,46-49. Indeed, 
one study demonstrated an inverse correlation between neutrophil counts and the risk of TB infection in 
contacts of patients diagnosed with pulmonary TB47, consistent with an early protective role for this cell 
population.  
Our demonstration that neutrophil gene expression patterns, but not neutrophil counts themselves, predict 
outcome in RhCMV/TB-vaccinated RM, but not in unvaccinated and i.d. BCG-only vaccinated RM 
suggests that neutrophils might be important co-effectors for RhCMV/TB vaccine-elicited T cell 
responses, and that their differentiation or activation state determines, at least in part, their ability to 
contribute to RhCMV/TB vaccine-mediated protection. Interestingly, it appears that the protection-
associated transcriptomic signature in neutrophils primarily delineates RhCMV/TB-vaccinated RM 
destined for complete or nearly complete protection from those with partial or no protection (Fig. 6), 
suggesting that the contribution of “primed” neutrophils to protection occurs very early after challenge 
and wanes thereafter. The extent to which this protective neutrophil differentiation/activation state is 
related to RhCMV/TB vaccination, monkey genetics, or immune events at the time of challenge remains 
to be determined, but it is notable that i.d. BCG vaccination prior to RhCMV/TB vaccination appears to 
deleteriously modify the expression of several of the protection-associated genes (Fig. 6), suggesting that 
innate immune modulation might account for the apparent anti-protective effect of giving i.d. BCG 6 
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weeks prior to RhCMV/TB vaccination. Additional studies to determine the effect of remote BCG 
vaccination on RhCMV/TB vector-mediated protection will be required to clarify the potential clinical 
significance of this putative antagonistic effect in at risk populations with previous BCG vaccination.  
In summary, the data presented here demonstrate that RhCMV-based vaccines manifest significant 
protection against aggressive Erdman-strain TB in highly susceptible RM. Although delineation of the 
specific immunologic mechanisms responsible for protection in RhCMV/TB-vaccinated individuals will 
require additional study, the nature of RhCMV/TB vector immunogenicity and the dynamics of protection 
after challenge suggests that protection is based on both the ability of this persistent viral vector to elicit 
and maintain Mtb-specific effector-differentiated resident memory T cell responses, and on a conducive 
innate immune state at the time of Mtb challenge that might also be vaccine-related50,51. Importantly, it has 
been documented in natural CMV infection that the robust TTrEM/TEM responses elicited by this virus are 
maintained for life19,20. To our knowledge, CMV is unique in this ability, and recent data indicates that 
strategically attenuated CMV vectors, potentially safe enough for clinical translation, maintain this unique 
immunogenicity (Hansen, Früh and Picker, unpublished data). How the above described putative 
interaction between CMV vaccine-elicited TTrEM/TEM and BCG-/Mtb-elicited immune regulation will play 
out over clinically relevant timeframes in people remains to be determined. However, the ability of 
RhCMV/TB vaccination to completely prevent development of TB disease in more than 40% of 
vaccinated RM and to provide a nearly 70% overall vaccine effect offers promise that a human CMV/TB 
vaccine might be effective in preventing pulmonary TB in adolescents and adults52, and thereby contribute 
to ending the global TB epidemic. 
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FIGURE LEGENDS 
Figure 1: Immunogenicity of RhCMV/TB and i.d. BCG vaccines (Study 1). (a) Schematic of the RM 
groups, (n=29 biologically independent animals), vaccination and challenge protocols, and necropsy time 
points of Study 1. (b) Longitudinal analysis of the overall CD4+ and CD8+ T cell response to the 9 Mtb 
insert proteins after vaccination. The background-subtracted frequencies of cells producing TNF and/or 
IFN-g by flow cytometric ICS assay to peptide mixes comprising each of the Mtb proteins within the 
memory CD4+ or CD8+ T cell subsets were summed with the figure showing the mean (+ SEM; n=7 per 
group) of these overall (summed) responses at each time point. (c) Boxplots compare the individual Mtb 
protein (each of the 9 Mtb inserts plus the non-insert CFP-10)-specific and overall (summed) Mtb-specific 
CD4+ and CD8+ T cell response frequencies (defined by TNF and/or IFN-g production) in peripheral 
blood between the same vaccine groups at the end of the vaccine phase (each data point is the mean of 
response frequencies in 3 separate samples from weeks 44-49; ‡ indicates no response detected). (d) 
Boxplots compare the memory differentiation of the vaccine-elicited CD4+ and CD8+ memory T cells in 
peripheral blood responding to Ag85A with TNF and/or IFN-g production at the end of vaccine phase 
(week 47).  Memory differentiation state was based on CD28 vs. CCR7 expression, delineating central 
memory (TCM), transitional effector memory (TTREM), and effector memory (TEM), as designated. (e) 
Boxplots compare the frequency of vaccine-elicited CD4+ and CD8+ memory T cells in peripheral blood 
responding to Ag85A with TNF, IFN-g and IL-2 production, alone and in all combinations at the end of 
vaccine phase (week 49). (f) Boxplots compare the individual Mtb protein-specific and overall (summed) 
Mtb-specific CD4+ and CD8+ T cell response frequencies (defined by TNF and/or IFN-g production) in 
bronchoalveolar lavage (BAL) fluid between the vaccine groups at the end of the vaccine phase (weeks 
46-47). In c-f, plots show a box from 1st to 3rd quartiles (IQR) and a line at the median, with whiskers 
extending to the farthest data point within 1.5*IQR above and below the box respectively; all data points 
outside of the whiskers are plotted individually; the Kruskal-Wallis (KW) test was used to determine the 
significance of differences between vaccine groups with the Wilcoxon rank sum test used to perform pair-
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wise analysis if KW p-values were ≤0.05; brackets indicate pair-wise comparisons with Holm-adjusted, 
two-sided Wilcoxon p-values ≤0.05 (with actual p-values shown; n=7 per group). 
Figure 2: Outcome of Mtb challenge (Study 1). (a) Development of peripheral blood CD4+ T cell 
responses to the peptide mixes comprising the non-vaccine insert Mtb protein CFP-10 after Mtb challenge 
by flow cytometric ICS analysis (response defined by TNF and/or IFN-g production after background 
subtraction in memory subset; CFP-10-specific CD8+ T cell responses shown in Supplementary Fig. 2a). 
(b) Mean (+ SEM; n=7 per group) change in peripheral blood CD4+ T cell response frequencies to peptide 
mixes comprising the vaccine insert Mtb proteins after Mtb challenge from pre-challenge baseline by flow 
cytometric ICS analysis (response defined as in a; analogous CD8+ T cell responses shown in 
Supplementary Fig. 2b). There were no significant differences in post-challenge change-from-baseline 
response dynamics between unvaccinated RM and any of the vaccine groups (see Methods). (c) CT 
quantification of disease volume in the pulmonary parenchyma after Mtb challenge (presence or absence 
of draining LN enlargement indicated by closed vs. open symbols). (d) Boxplots compare the AUC of 
CT-determined pulmonary lesional volume (day 0-112; see Methods) of the 4 RM groups. (e-g) Boxplots 
compare the extent of TB at necropsy measured by Mtb recovery with mycobacterial culture and by 
pathologic disease score (see Methods) in lung parenchyma (e), all non-lung parenchymal tissues (f) and 
all tissues (g). In d-g, plots show jittered points with a box from 1st to 3rd quartiles (IQR) and a line at the 
median, with whiskers extending to the farthest data point within 1.5*IQR above and below the box 
respectively; unadjusted two-sided Wilcoxon p-values ≤0.05 are shown (see also Supplementary Fig. 
4a); n=7 per vaccine group and n=8 unvaccinated RM. 
Figure 3: Immunogenicity of RhCMV/TB vaccines (Study 2). (a) Schematic of RM groups, 
vaccination and challenge protocols, and necropsy time points of Study 2 (n=36 biologically independent 
animals). (b) Longitudinal analysis of the overall CD4+ and CD8+ T cell response to the 9 Mtb Ags after 
vaccination, as described in Fig. 1b (n=9 per group). (c) Boxplots compare the individual Mtb protein 
(each of the 9 Mtb inserts plus the non-insert CFP-10)-specific and overall (summed) Mtb-specific CD4+ 
and CD8+ T cell response frequencies (defined by TNF and/or IFN-g production) in peripheral blood 
between the vaccine groups at the end of the vaccine phase (each data point is the mean of response 
frequencies in 3 separate samples from weeks 49-55; ‡ indicates no response detected). (d) Boxplots 
compare the memory differentiation (see Fig. 1d) of the vaccine-elicited CD4+ and CD8+ memory T cells 
in peripheral blood responding to Ag85A with TNF and/or IFN-g production at the end of vaccine phase 
(weeks 51-52). (e) Boxplots compare the frequency of vaccine-elicited CD4+ and CD8+ memory T cells in 
peripheral blood responding to Ag85A with TNF, IFN-g and/or IL-2, alone and in all combinations at the 
end of vaccine phase (weeks 49-50). (f,g) Boxplots compare the individual Mtb protein (the 9 Mtb inserts 
plus the non-insert CFP-10)-specific and overall (summed) Mtb-specific CD4+ and CD8+ T cell response 
frequencies (defined by TNF and/or IFN-g production) in BAL (f) and in peripheral LN (g) between the 
vaccine groups at the end of vaccine phase (weeks 46-47). In c-g, plots show a box from 1st to 3rd 
quartiles (IQR) and a line at the median, with whiskers extending to the farthest data point within 
1.5*IQR above and below the box respectively; all data points outside of the whiskers are plotted 
individually. Statistics were performed as described in Fig. 1 with brackets indicating pair-wise 
comparisons with Holm-adjusted, two-sided Wilcoxon p-values ≤0.05 (with actual p-values shown; n=9 
per group). 
Figure 4: Outcome of Mtb challenge (Study 2 and Overall). (a,b) Development of peripheral blood 
CD4+ T cell responses to the peptide mixes comprising the non-vaccine insert Mtb protein CFP-10 in all 
Study 2 RM (a), and comprising the Ag85B, Rv1733 and Rpf C proteins in group 3 RM only (b; RM 
vaccinated with the single 68-1 RhCMV/TB-6Ag vector lacking these 3 inserts) after Mtb challenge by 
flow cytometric ICS analysis, as described in Fig. 2a (peripheral blood CD8+ T cell responses and tissue 
CD4+ and CD8+ T cell responses to these same Ags are shown in Supplementary Figs. 2c,d and 8, 
respectively). (c) Mean (+ SEM; n=9 per group) change in peripheral blood CD4+ T cell response 
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frequencies to peptide mixes comprising the vaccine insert Mtb proteins after Mtb challenge from pre-
challenge baseline by flow cytometric ICS analysis, as described in Fig. 2b (analogous CD8+ T cell 
responses shown in Supplementary Fig. 2e). Holm-adjusted Wilcoxon p-values ≤0.05 are shown for 
change-from-baseline AUC of post-challenge responses in any of the vaccinated groups versus the 
unvaccinated controls. (d) CT quantification of disease volume in the pulmonary parenchyma after Mtb 
challenge (presence or absence of draining LN enlargement indicated by closed and open symbols, 
respectively). (e) Boxplots compare the AUC of CT-determined pulmonary lesional volume (day 0-112) 
of the unvaccinated RM vs. all RhCMV/TB-vaccinated RM vs. RM in each individual RhCMV/TB 
vaccine group (n=9 per group). (f-h) Boxplots compare the extent of TB at necropsy measured by Mtb 
recovery with mycobacterial culture and by pathologic disease score in lung parenchyma (f), all non-lung 
parenchymal tissues (g) and all tissues (h) in the same RM groups. (i,j) The boxplots and unadjusted two-
sided Wilcoxon test p-values compare the outcome of Mtb challenge in all unvaccinated RM vs. all 
RhCMV/TB only-vaccinated RM across both Study 1 (n=8 vs. n=7) and Study 2 (n=9 vs. n=27) using a 
scaled outcome measure that combines both Mtb culture and pathologic score data (see Methods). In (j), 
the RhCMV/TB-vaccinated RM are divided into 2 groups based on presence (n=20) or absence (n=14) of 
granulomatous disease at necropsy (necropsy pathologic score ≥4 vs. =0, respectively) vs. n=17 
unvaccinated RM. In e-j, plots show jittered points with a box from 1st to 3rd quartiles (IQR) and a line at 
the median, with whiskers extending to the farthest data point within 1.5*IQR above and below the box 
respectively (unadjusted, two-sided Wilcoxon p-values ≤0.05 are shown; see also Supplementary Fig. 4). 
Figure 5: Transcriptional response to Mtb challenge reduced in protected RM. (a) The median 
longitudinal log2 gene expression fold-change between 28 days after challenge and the day of challenge 
in unvaccinated RM from Study 1 and 2 (n=13; y-axis) is plotted against the average median log2 
expression difference computed between HIV-negative active TB patients and latent TB infection controls 
from South Africa (TB: n=46, LTBI: n=48) and Malawi (TB: n=51, LTBI: n=35) (x axis) for 3406 
significantly regulated genes identified in the human study37. Genes significantly regulated in Mtb-
challenged, unvaccinated RM are shown in red (one-sided, paired Wilcoxon rank sum test, p<0.05; 
FDR<0.33; complete list of p-values shown in Supplementary Table 1). The overall Spearman rank 
correlation coefficient between expression fold-changes in the human study and RM for all 3406 genes is 
0.58. (b) Commonly up-regulated (n=793) or down-regulated (n=689) genes in humans with TB disease 
and unvaccinated Study 1 + 2 RM (n=13) 28 days after Mtb infection from panel a were tested for 
significant over-representation of transcriptional modules53 and immune pathways (Reactome)54 (p<0.002, 
FDR<0.01;one-sided Fisher’s Exact Test), which were then color-coded according to significance and 
pathway membership. Enrichment p-values ranged from p<10-40 for inflammation and interferon, to 
p=2x10-3 for Class I MHC (complete list of p-values shown in Supplementary Table 2). (c) The heatmap 
depicts scaled expression fold-changes for all 214 genes (rows) for all Study 1 and 2 RM (columns; n=59) 
ordered by scaled combination outcome measure (red bar at top). Post-challenge expression fold-changes 
for 214/1482 commonly regulated genes in panel a were strongly associated with the scaled combination 
outcome measure as indicated by Poisson modeling (p<0.05, FDR<0.1; complete list of p-values shown in 
Supplementary Table 3). Genes with fold-changes positively associated with outcome are significantly 
enriched for the interferon transcriptional module (FDR=3x10-27) and other pathways (Supplementary 
Table 4). Day 28/Day of challenge log2 fold-changes were scaled by the maximum absolute log2 fold-
change observed. Annotations of genes to significantly over-represented pathways are shown in colored 
boxes at the left side of the heatmap. (d) Heatmap as in panel c showing expression profiles of 46 genes 
from the interferon transcriptional module. (e) Scatterplots depicting scaled combination outcome 
measure (y axis) as a function of Day 28/Day of challenge log2 fold-changes for representative genes 
from the interferon transcriptional module. The dashed line indicates the best-fit Poisson model. P-values 
indicate the significance of the regression coefficient in a sandwich-adjusted Poisson model (n=59) for the 
association between gene expression and the scaled combination outcome measure. 
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Figure 6: Pre-challenge transcriptional profiles correlate with post-challenge outcome in 
RhCMV/TB-vaccinated RM. (a) Heatmap visualization of the relative gene expression (log2 expression 
fold-change) of genes expressed in the whole blood immediately prior to challenge of RhCMV/TB-
vaccinated RM (with or without i.d. BCG) from Study 1 + 2 that are significantly associated with the 
scaled combination outcome measure by Poisson modeling (p<0.05, FDR<0.33; FDR values are shown in 
the heatmap and all p-values are shown in Supplementary Table 5; n=40 RM), and are not associated with 
outcome for the unvaccinated and i.d. BCG-vaccinated RM (p>0.2; n=19 RM). The left and right sides of 
the heatmap show expression of the genes in RhCMV/TB-vaccinated vs. unvaccinated or i.d. BCG-
vaccinated RM, respectively. The heatmap also delineates whether the expression of each gene correlates 
with the absolute counts of any of the designated leukocyte populations in the same blood sample (if more 
than one population correlates, the strongest association is shown; complete results are shown in 
Supplementary Table 7). Note that genes positively associated with eventual disease are significantly 
enriched for genes associated with T cell counts (FDR<0.05; one-sided Fisher’s Exact Test; p-values 
values provided in Supplementary Table 8), whereas genes negatively associated with eventual disease 
(positively correlated with RhCMV/TB-mediated protection) are significantly enriched for genes 
associated with neutrophil counts (FDR=3x10-3). (b) The testing of genes in panel a (protection signature: 
n=77 genes; susceptibility signature: n=181 genes) for over-representation of transcriptional modules and 
pathways revealed three significant results (p<0.05, FDR<0.15, one-sided Fisher’s Exact Test), indicated 
by the colored bars on the left of the heatmap (p-values provided in Supplementary Table 6). The heatmap 
shows the relative expression of specific genes (same scale as in panel a) with pre-challenge associations 
with the scaled combination outcome measure that belong to the significantly enriched modules and 
pathways. (c) Scatterplots depicting scaled combination outcome measure (y-axis) as a function of pre-
challenge expression of representative protection-associated genes from the neutrophil degranulation 
module (MMP8 and OLFM4, the latter expressed by a neutrophil subset55), as well as CD52, a broadly 
expressed gene that is also expressed by neutrophils56. The dashed line indicates the best-fit Poisson 
model (The p-values shown indicate the sandwich-adjusted Poisson p-values for the association between 
pre-challenge gene expression and the scaled combination outcome measure; n=40 RM). (d) Heatmap 
visualization of 15 genes from panel a with protection-associated pre-challenge expression levels which 
exhibit significantly reduced expression on the day of challenge (one-sided Wilcoxon tests p<0.05, 
FDR<0.33) in RM vaccinated with i.d. BCG prior to RhCMV/TB vaccination (n=7) compared to RM 




Rhesus Macaques. Sixty-five purpose-bred, pedigreed, male RM (Macaca mulatta) of Indian genetic 
background were used in the described studies. At assignment, these RM were specific-pathogen free 
(SPF) as defined by being free of Macacine herpesvirus 1, D-type simian retrovirus, simian T-
lymphotrophic virus type 1, simian immunodeficiency virus, and Mtb, but were all naturally RhCMV-
infected. All RM used in this study were housed at the Oregon National Primate Research Center 
(ONPRC) in Animal Biosafety level (ABSL)-2 (vaccine phase) and ABSL-3 rooms (challenge phase) 
with autonomously controlled temperature, humidity, and lighting. RM were single cage-housed due to 
the infectious nature of the study and had visual, auditory and olfactory contact with other animals. 
Because the RM were single cage-housed, an enhanced enrichment plan was designed and overseen by 
nonhuman primate behavior specialists. RM were fed commercially prepared primate chow twice daily 
and received supplemental fresh fruit or vegetables daily. Fresh, potable water was provided via automatic 
water systems. All RM were observed twice daily to assess appetite, attitude, activity level, hydration 
status and evidence of disease (tachypnea, dyspnea, coughing). Physical exams including body weight and 
complete blood counts were performed at all protocol time points. RM care and all experimental protocols 
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and procedures were approved by the ONPRC Institutional Animal Care and Use Committee (IUCUC). 
The ONPRC is a Category I facility. The Laboratory Animal Care and Use Program at the ONPRC is 
fully accredited by the American Association for Accreditation of Laboratory Animal Care (AAALAC), 
and has an approved Assurance (#A3304-01) for the care and use of animals on file with the NIH Office 
for Protection from Research Risks.  The IACUC adheres to national guidelines established in the Animal 
Welfare Act (7 U.S.C. Sections 2131–2159) and the Guide for the Care and Use of Laboratory Animals 
(8th Edition) as mandated by the U.S. Public Health Service Policy. 
 
Animal Procedures. RM were sedated with ketamine HCl or Telazol® for intradermal and subcutaneous 
vaccine administration, venipuncture, bronchoalveolar lavage, LN biopsy, intrabronchial Mtb inoculation 
and computed tomography (CT) procedures. Mtb Erdman (kindly provided by Dr. J. Flynn, U. Pittsburgh) 
was diluted in saline, lightly sonicated and bacteria were delivered to a segmental bronchus in the right 
caudal lung lobe using a bronchoscope. The RM in Studies 1 and 2 received 25 and 10 colony forming 
units (CFU), respectively, in a volume of 1 ml57. Pre- and post-challenge axial CT scans (2.5 mm slices) 
were obtained using a multi-section CT scanner using helical technique, collimation 3 mm and pitch 1.5 
(CereTom, Neurologica Corp., Danvers, MA) and reconstructed as 1.25 mm slices to improve detection 
sensitivity58,59. Nonionic iodinated contrast (Isovue 370, 1-2 ml/kg, Bracco Diagnostics, Princeton, NJ) 
was administered IV at a rate of 1-2 ml/s. CT scans were obtained with 120 kVp and 200 mA.  All RM 
were imaged pre-challenge, at two-week intervals for the duration of the studies and immediately prior to 
necropsy. Scans were interpreted by a veterinarian who was blinded to the study group of the subject. 
Lesion area in sequential scans was determined from transverse slices through entire lung fields using the 
IMPAX 6.5.5.3020 software area tool (AGFA HealthCare N.V., Mortsel, Belgium) and lesion volume 
determined by multiplying area by 1.25. One RM developed extensive bilateral miliary disease with 
estimated lesion volume >200,000 mm3 and no further attempts to estimate lesion volume were made in 
this animal.    
 
Necropsy. The humane criteria for removing RM with end-stage TB from the studies are as follows: 1) 
marked lethargy, 2) severe dyspnea at rest and/or failure to maintain adequate oxygenation (85%) based 
on pulse oximetry or blood gas analysis, 3) hemoptysis, 4) weight loss (>15% in 2 weeks; >25% over any 
time course in an adult animal), 5) hypothermia <96°F with supplemental heating, 6) persistent anemia 
(<20% for 2 weeks), 7) dehydration unresponsive to oral rehydration therapy for 3 days, 8) non-
responsiveness to therapy for spontaneous disease conditions, 9) poor appetite, requiring more than 3 
orogastric tube feedings in 7 days, 10) obtundation, 11) neurologic deficits, and 12) persistent self-
injurious behavior unresponsive to a change in location or enrichment. RM that manifested one or more of 
these end-stage criteria were immediately necropsied. RM that remained clinically well after post-
infection week 16 were randomized and scheduled for euthanasia and necropsy at the rate of two per 
week. There were 3 exceptions to this general rule of necropsy initiated by end-stage disease criteria or 
randomization (3 necropsies that are designated as “other” in Fig. 1a). One non-end-stage RM (D1) in 
Study 1 was euthanized on the same day as an end-stage RM because the IACUC does not permit housing 
a single RM alone in a room. Two additional RM (N1, N3) in Study 1 were euthanized because of failure 
to maintain adequate oxygenation following a bronchoalveolar lavage procedure that was not attributable 
to end-stage Mtb disease. To avoid this issue in Study 2, BALs were not performed after challenge. 
At the humane or scheduled endpoint RM were euthanized with sodium pentobarbital overdose (>50 
mg/kg) and exsanguinated via the distal aorta. The necropsy procedure included complete gross 
pathologic evaluation of abdominal organs and tissues and the brain prior to entering the thoracic cavity to 
avoid contamination. Macroscopic granulomas in liver, spleen, kidney and the brain were counted, 
measured and photographed in serial 5 mm tissue slices whereas granulomas occurring in extra-thoracic 
LNs, the gastrointestinal tract and soft tissues were collected, measured and photographed with minimum 
sectioning and given a numeric point value score using a semi-quantitative grading system 
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(Supplementary Fig. 3). Granulomas (≤10) occurring in these tissues were bisected and one half 
collected in sterile media tubes for Mtb culture (see below) and the remaining half immersed in 10% 
neutral-buffered formalin for histologic analysis. Representative granulomas were selected for Mtb culture 
and histology from tissues with >10 granulomas. Single small granulomas (≤1 mm) were utilized entirely 
for bacteriology. If no granulomas were identified, representative samples of selected tissues (see below) 
were submitted for Mtb culture. Representative samples of all abdominal and mediastinal organs and 
associated major LN groups, and both the brain and spinal cord were collected and then fixed in 10% 
neutral-buffered formalin for histologic analysis. Additional samples from these tissues were collected for 
mononuclear isolation. The pleura and thoracic wall were examined on entering the thoracic cavity and 
macroscopic granulomas and adhesions were collected, counted, measured, photographed, scored as 
described (Supplementary Fig. 3) and sampled for bacteriology and histology. The thoracic viscera were 
removed en bloc, and then transferred to a sterile cutting board for examination and dissection. Extreme 
care was taken to avoid Mtb contamination of thoracic tissues by spillage of granuloma contents during 
dissection, and this was accomplished in all but 1 RM in which gross spillage of granuloma contents was 
observed upon opening the thoracic cavity. The heart was removed and examined, and pulmonary and 
mediastinal LNs and individual lung lobes were dissected free, weighed and photographed. LNs were 
divided into samples for Mtb culture, histopathology, and mononuclear cell isolation (with Mtb culture 
prioritized if tissue was limiting). Macroscopic granulomas in individual lung lobes were counted, 
measured, photographed and scored in serial 5 mm tissue slices. Samples for Mtb culture from the right 
and left lung slices were harvested using a nonbiased, stereologic sampling method60. Briefly, an opaque 
plastic 96 hole strip-tube rack was placed over the adjacent lung slices and individual 5 mm lung tissue 
cores (30 from the right lung and 10 from the left lung) were collected through these the openings in the 
rack (irrespective of any gross pathology) in a consistent pattern across all study monkeys. These 
stereologically-obtained (essentially random) lung cores were bisected and one-half processed for 
bacteriology and the remaining half immersed in 10% neutral-buffered formalin for histologic analysis. In 
addition, as indicated above, extensive representative samples of all lung lobes and lung-draining LN, all 
abdominal and mediastinal organs/tissues and all major non-lung-draining LN groups were collected and 
immersed in 10% neutral-buffered formalin for histologic analysis. Tissues for histologic analysis were 
routinely processed and embedded in paraffin. Sections (6 mm) were stained with hematoxylin and eosin. 
All told, between 100 and 120 tissue blocks were examined by a veterinary pathologist for each monkey 
necropsy, ~50 of which focused on the lung, trachea/major bronchi, and lung draining LNs, and the 
remainder all the other non-pulmonary tissues. Selected tissues were stained by the Ziehl-Neelsen method 
for acid-fast bacteria. 
 
Vaccines. The 68-1 and 68-1.2 RhCMV/TB vectors were constructed by bacterial artificial chromosome 
(BAC) recombineering and were reconstituted and amplified into vector preparations as previously 
described22-24,33. The Mtb Ags to be included in these vectors were selected by a bioinformatics selection 
criteria starting with the scoring of 4000 Mtb open reading frames (ORF) by 11 criteria61. Those criteria 
included immunogenicity, vaccine efficacy, expression in granulomas, secretion, and role in hypoxic 
survival.  The top candidates were then further screened by a deeper bioinformatics analysis of predicted 
T cell epitopes and curated to include antigens that are active during different stages of TB infection. In 
addition, all antigens had been shown to be at least partially protective in a mouse challenge model. The 
final choice of 9 Mtb proteins for the vaccine inserts included 3 representative proteins from so-called 
acute phase (85A, 85B, ESAT-6), latency (Rv1733, Rv3407, Rv2626) and resuscitation (Rpf A, Rpf C 
and Rpf D) classes of Mtb Ags.  These 9 Ags were expressed in 4 different RhCMV/TB vectors (to be 
used in combination) for both the 68-1 and 68-1.2 backbones, as follows: 1) Ag85A/Ag85B/Rv3407 
(GenBank #KY611401), 2) Rv1733/Rv2626 (GenBank #KY611402), 3) Rpf A/Rpf C/Rpf D (GenBank 
#KY611403), and 4) Ag85B/ESAT-6 (GenBank #KY611404). The GenBank Accession # corresponds to 
the sequences as they are found in the final vectors. Polyprotein #s 1-3 were inserted into the nonessential 
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Rh211 ORF under the control of the murine CMV IE promotor. Polyprotein #4 was inserted in the same 
region of the RhCMV genome but under the control of the EF1a promotor (Supplementary Fig. 1a). For 
the single 6 Ag-expressing, 68-1 RhCMV/TB vector, a single polyprotein insert consisting of 2 Ags from 
each of 3 classes described above (acute: ESAT-6, Ag85A; latency: Rv3407, Rv2626; resuscitation: 
RpfA, RpfD; GenBank #KY611405) was used to replace the nonessential Rh107 gene, placing its 
expression under the control of the endogenous Rh107 promoter (Supplementary Fig. 1a). All BACs 
were analyzed by restriction digestion to confirm genomic integrity and were further examined by next 
generation sequencing (NGS) on an Illumina MiSeq sequencer to ensure the absence of any unintended 
mutations in the transgene. Full genome sequences of viral DNA isolated from vaccine stocks used in the 
presented study [68-1 RhCMV/85A/85B/Rv3407 (MF468139); 68-1.2 RhCMV/85A/85B/Rv3407 
(MF468141); 68-1.2 RhCMV/85B/ESAT-6 (MF468142); 68-1.2 RhCMV/Rpf A/Rpf C/Rpf D 
(MF468143); 68-1.2 RhCMV/Rv1733c/Rv2626c (MF468144); 68-1 RhCMV/Rpf A/Rpf C/Rpf D 
(MF468145) and 68-1 RhCMV/Rv1733c/Rv2626c (MF468146)] or full genome sequences of the BAC of 
the mutant used to derive the vaccine stocks [68-1 RhCMV/85B/ESAT-6 (MF468140) and 68-1 ΔRh107 
RhCMV/TB-6Ag (MF468147)] were submitted to GenBank. To reconstitute the vaccine vectors, the 
BACs were electroporated into telomerized or primary rhesus fibroblasts and kept in culture until full 
cytopathic effect was achieved. At this point, transgene expression was confirmed by immunoblot of 
infected cell lysates and vaccine stocks were generated by the ONPRC Molecular Virology Support Core. 
Overall genomic integrity and transgene expression of the final vaccine stocks were confirmed by 
immunoblots, NGS, and pilot immunogenicity studies in RM. Expression of the ORFs neighboring the 
TB Ag insertion site was confirmed by RT-PCR. RhCMV/TB vector stocks were titered using primary 
rhesus fibroblasts in a TCID50 assay. Study 1 and 2 RM were vaccinated by subcutaneous administration 
of 5 x 106 pfu of each of the designated RhCMV/TB vectors.  For the RM receiving the 4 vector set, each 
vector was administered in a separate limb (right arm, left arm, right leg, left leg). RM were given the test 
vaccines twice, with the second dose (homologous boost) administered 15 weeks (Study 1) or 14 weeks 
(Study 2) after the first dose. The BCG vaccine (Danish strain 1331; Batch #111005A) was obtained from 
the Statens Serum Institute (Copenhagen, Denmark) and was reconstituted per the manufacturer’s 
instructions (Diluent Batch #386587B). RM were BCG-vaccinated by the intradermal administration of 
100 µl of vaccine containing 5.5 x 105 CFUs into the mid-back. 
 
Immunologic Assays. Mtb-specific CD4+ and CD8+ T cell responses were measured in blood, BAL and 
tissues by flow cytometric ICS, as previously described in detail22,25,33. Briefly, mononuclear cell 
preparations from blood, BAL or tissue were incubated at 37oC in a humidified 5% CO2 atmosphere with 
overlapping, consecutive 15mer peptide mixes (11 amino acid overlap) comprising these proteins, or 
individual 15mer peptides from these proteins, and the co-stimulatory molecules CD28 and CD49d (BD 
Biosciences) for 1 hour, followed by addition of Brefeldin A (Sigma-Aldrich) for an additional 8 hrs. Co-
stimulation without antigenic peptides served as a background control. As previously described25, the 
MHC restriction (MHC-Ia, MHC-E, MHC-II) of a peptide-specific response was determined by pre-
incubating isolated mononuclear cells for 1 hr at room temperature (prior to adding peptides and 
incubating per the standard ICS assay) with the following blockers: 1) the pan anti-MHC-I mAb W6/32 
(10mg/ml), 2) the MHC-II-blocking CLIP peptide (MHC-II-associated invariant chain, amino acids 89-
100; 20μM), and 3) the MHC-E-blocking VL9 peptide (VMAPRTLLL; 20μM). Blocking reagents were 
not washed, but remain throughout the assay. Following incubation, stimulated cells were fixed, 
permeabilized and stained as previously described22,25,33 using combinations of the following 
fluorochrome-conjugated mAbs: SP34-2 (CD3; Pacific Blue, Alexa700), L200 (CD4; AmCyan, BV510), 
SK-1 (CD8a; PerCP-Cy5.5), MAB11 (TNF-α; FITC, PE), B27 (IFN-γ; APC), FN50 (CD69; PE, PE-
TexasRed), B56 (Ki-67; FITC), and in polycytokine analyses, JES6-5H4 (IL-2; PE, PE Cy-7). To 
determine the cell surface phenotype of Mtb-specific CD4+ and CD8+ T cells, mononuclear cells were 
stimulated as described above, except that the CD28 co-stimulatory mAb was used as a fluorochrome 
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conjugate to allow CD28 expression levels to be later assessed by flow cytometry, and in these 
experiments, cells were surface-stained after incubation for lineage markers CD3, CD4, CD8, CD95 and 
CCR7 (see below for mAb clones) prior to fixation/permeabilization and then intracellular staining for 
response markers (CD69, IFN-γ, TNF-α; note that Brefeldin A treatment preserves the pre-stimulation 
cell-surface expression phenotype of phenotypic markers examined in this study). Data was collected on 
an LSR-II (BD Biosciences). Analysis was performed using FlowJo software (Tree Star). In all analyses, 
gating on the lymphocyte population was followed by the separation of the CD3+ T cell subset and 
progressive gating on CD4+ and CD8+ T cell subsets. Antigen-responding cells in both CD4+ and CD8+ T 
cell populations were determined by their intracellular expression of CD69 and one or more cytokines 
(either or both of the IFN-γ and TNF; ± IL-2 in polycytokine analyses). After subtracting background, the 
raw response frequencies above the assay limit of detection were “memory-corrected” (e.g., % responding 
out of the memory population), as previously described22,23 using combinations of the following 
fluorochrome-conjugated mAbs to define the memory vs. naïve subsets SP34-2 (CD3; Alexa700, PerCP-
Cy5.5), L200 (CD4; AmCyan), SK-1 (CD8a; APC, PerCP-cy-5.5), MAB11 (TNF-α; FITC), B27 (IFN-γ; 
APC), FN50 (CD69; PE), CD28.2 (CD28; PE-TexasRed), DX2 (CD95; PE), 15053 (CCR7; Pacific Blue), 
and B56 (Ki-67; FITC). As previously described21, assay background is determined by measurement of 
the net response to the Ags of interest in a cohort of monkeys that have never been exposed to these Ags. 
We, conservatively, use 4 standard deviations above the mean of these background values as our cut-off 
value or 0.05%, whichever is higher (responses below this cut-off are considered negative or response = 
0). For this study, the net responses to the 10 Mtb Ags in blood in all the quantiferon-negative RM pre-
vaccination, was determined to be 0.004% ± 0.004% for CD4+ T cells (cut-off = 0.02%) and 0.003% ± 
0.004 for CD8+ T cell responses (cut-off = 0.02%). For BAL, the mean background + SD was determined 
to be 0.004% ± 0.008% for both CD4+ and CD8+ T cells (cut-off = 0.036%).  Since these cut-off levels 
were all <0.05%, we used our conservative default cut-off of 0.05% for all responses. For memory 
phenotype and polycytokine analysis of Mtb Ag-specific T cells, all cells expressing CD69 plus one or 
more cytokines were first Boolean gated, and then this overall Ag-responding population was subdivided 
into the subsets of interest on the basis of surface phenotype or cytokine production pattern22,23. 
A customized Luminex subclass assay63 was used to quantify the relative concentration of each 
Immunoglobulin (Ig) isotype among Mtb antigen-specific Abs. Carboxylated microspheres (Luminex) 
were coupled with Mtb protein Ags by covalent NHS-ester linkages via EDC and NHS (Thermo 
Scientific) per the manufacturer’s instructions. Ag-coated microspheres (5000 per well) were added to a 
96-well filter plate (Millipore). Each Ig sample (5 µg) was added to five replicate wells of a 96-well plate 
and incubated for 16 hrs at 4°C. The microspheres were washed and the Ig isotype-specific detection 
reagents were added (Southern Biotech) for 2 hr at room temperature. The beads were then washed and 
read on a Bio-Plex 200 System. The background signal, defined as mean fluorescent intensity (MFI) of 
microspheres incubated with PBS, was subtracted. Each sample was tested twice. 
 
Mycobacterial (Mtb) Culture. Tissues routinely collected at necropsy for Mtb burden analysis in both 
Study 1 and 2 included:  30 stereologic punches from right lung lobes, 10 punches from left lung lobes, 
trachea, left hilar LN, right hilar LN, left carinal LN, right carinal LN, paratracheal LN, mediastinal LN, 
axillary LN, inguinal LN, mesenteric LN, spleen, pancreas, left medial lobe of liver, right medial lobe of 
liver, left lateral lobe of liver, right lateral lobe of liver, liver caudate, left kidney, and right kidney.  In 
Study 2 we also collected and cultured retropharyngeal LN, tonsil, submandibular LN, and iliosacral LN. 
In one RM in Study 2, Mtb culture analysis was not reported due to gross contamination of thoracic 
tissues with granuloma contents. Tissues were collected in HBSS and were then homogenized in an IKA 
grinder tube with an IKA Ultra-Turrax Tube Drive homogenizer. The tissue homogenate was then filtered 
over a 70µm wire screen to remove debris and 200µl of this material was plated neat and in serial 
dilutions (1/10, 1/100) on 7H11 agar plates (Remel). All plates were incubated at 37oC and M. 
tuberculosis growth was enumerated 28 and 42 days later. A tissue was considered Mtb+ if any colonies 
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with the correct morphologic features were identified. Selected cultures were analyzed by the Ziehl-
Neelsen method for acid-fast bacteria to confirm colony morphology. Bacterial density in lung-draining 
LNs was calculated in CFU per gram of tissue. 
 
Data Preparation (Immunology and Vaccine-Mediated Protection)  
Area under the log CT scan-determined pulmonary disease volume curve. We computed the AUC of the 
log-transformed CT scan-determined pulmonary disease volume measurements from time 0 (set to 0) to 
day 112. Next, we imputed missing values for monkeys taken to necropsy before the full series of 
scheduled CT scan time points. We computed the AUC of this augmented data. The imputation procedure 
that we employed used linear regression to estimate missing values from previous time points. As a 
sensitivity analysis, we also imputed the missing values using a more conservative rule (replacing missing 
values with the largest non-missing value at the same time point among monkeys receiving the same 
treatment, excluding for further conservatism one high-valued outlier unvaccinated RM); the resulting 
AUCs were highly insensitive to this procedure (Pearson correlation over 0.99 for both studies). 
Necropsy score data. The non-negative count-valued necropsy scores are amenable to Poisson modeling. 
Model evaluations supported inclusion of the additional parameter for overdispersion in the negative 
binomial model. In TB Study 2 the estimated extra parameter was zero, so this model was equivalent to a 
simple Poisson model. For this Poisson modeling we employed sandwich-based estimates of variance-
covariance matrices as an alternative method to account for overdispersion, using the vcovHC function in 
the sandwich package in R62-64. We also considered and rejected employing the zero-inflated Poisson (ZIP) 
model.  
Necropsy culture data. Necropsy culture inputs were quantitative measures of culture growth with 
multiple replicates per tissue. We treated these data as binary indicators of a culture being positive vs. 
negative (zero), and evaluated the total number of positive cultures. Model evaluations of necropsy 
culture outcome data favored the more expressive negative binomial models over Poisson models, and did 
not support using the ZIP model. Note that one animal in TB Study 2 (I3; see Supplementary Fig. 9) was 
missing necropsy culture data but did have necropsy score data; the analyses of the culture data therefore 
excluded this RM. Thus, for the left panels of Fig. 4f-h (“Positive Mtb cultures”), the sample size for the 
68-1.2-9Ag (green-colored) group is n = 8. As described below, we imputed the missing value for use in 
computing the scaled (normalized) combination outcome measure.  
Scaled (normalized) combination outcome measure. As shown in Supplementary Fig. 5, we found 
strong correlation between the necropsy score and necropsy culture outcome measures within each study, 
although the scales were different: necropsy cultures are about one-third as large as necropsy scores in 
both studies. We created the intermediate, study-specific scaled combination outcome measure to gain 
measurement precision by averaging these two very similar outcome measures. To ensure that each 
receives equal weight in the combined measure, and to maintain discreteness in support of Poisson 
analysis of the statistic, we first scaled the inputs by multiplying the necropsy culture values by 3 and then 
adding these to the necropsy scores. For Study 2, as indicated above, one RM (I3) had a missing necropsy 
culture value, so for this animal we computed the scaled combination outcome measure using an imputed 
necropsy culture value, which we obtained by multiplying the observed necropsy score value by the 
estimated coefficient from a simple linear regression model relating the two values. This monkey’s 
necropsy score value was 29, its imputed necropsy culture value was 8, and its scaled combination 
outcome measure value was 53. We employed a negative binomial regression model of these study-
specific combined measures versus treatment and study, and used the estimated coefficient on study 
(0.3796) to further scale the TB Study 1 scaled combination outcome values. Therefore, the scaled 
combination outcome variable for TB Study 1 RM is the study-specific value multiplied by 0.3796 and 
then rounded to maintain the discreteness of the final variable for Poisson analysis. 
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Challenge phase LN cell-forming units per gram. We computed the mean of log10-transformed 
measures of CFU per gram across five LN tissue samples (carinal left and right, and hilar left and right; 
paratracheal). The few missing values were first imputed using the mean value for the LN. 
End-of-vaccine-phase T cell response data. We also evaluated longitudinal flow cytometric ICS 
measures of CD4+ and CD8+ immune responses targeting the 9 individual genes in the RhCMV vaccines, 
and CFP-10. Our primary summary of these data was a measure of the immune response at the end of 
vaccine phase. These pre-challenge baseline immunogenicity values are geometric means of three 
independent measurements over the time periods shown in Figs. 1a and 3a. Totals over 6 or 9 antigens 
were computed prior to log-transformation and normalization. Normalization shifts and scales these 
values to have mean zero, standard deviation 1 so that units have the interpretation of z-scores measuring 
the number of standard deviations that an immune measurement (on the log scale) is from the overall 
(study-specific) mean of that measurement. 
Change-from-baseline T cell responses after Mtb challenge. We computed areas under the curve of 
time-varying differences from the pre-challenge baseline immunogenicity values for each of the 9 insert 
antigens over 42 or 98 days post-challenge (for TB Studies 1 and 2, respectively), on the natural (pre-log-
transformation and pre-normalization) scale. 
Antibody responses to vaccination. We computed log10 baseline-subtracted MFI values after replacing 
differences less than 1 by 1 (such that after log10-transformation these values are zero).  For plotting 
purposes, we computed positivity thresholds as the median among unvaccinated RM of the baseline-
subtracted measure prior to truncation and log transformation, plus three standard deviations. For TB 
antigens, we computed these threshold values separately for Study 1 and 2. For the SIV gp120 control Ag, 
which was used as a positive control using Ig obtained from 5 SIV-infected RM (SIVIG), we computed 
this background threshold using the unvaccinated RM from both studies (these values are plotted along 
with the SIVIG values in Supplementary Fig. 1b inset). 
 
Statistical Analysis (Immunology and Vaccine-Mediated Protection). All statistical analyses were 
conducted in R64.  [See also the Life Sciences Reporting Summary.] 
Sample size and treatment assignment. For both studies, the primary constraint on sample size was 
availability of RM subjects and BSL-3 facilities. Groups were balanced for monkey traits and treatments 
assigned non-randomly, but arbitrarily. 
Vaccine-mediated protection. As described above, we evaluated three primary outcome measures for 
evidence of a difference across treatment arms within each study: CT scan AUC from challenge to day 
112 post-challenge, pathologic score at necropsy, and extent of Mtb infection at necropsy (# Mtb+ 
tissues). The equivalence of the three Study 2 vaccine groups by these outcome measures 
(Supplementary Fig. 4) justified a pooled analysis. We employed non-parametric tests for primary 
comparisons and used parametric models for estimating confidence intervals of treatment effects. For 
comparisons of outcome measures across pairs of groups, we used two-sided Wilcoxon tests. Boxplots in 
Figs. 2 and 4 show unadjusted p-values of only the pairwise comparisons that are significant at the 0.05 
level. We employed Holm adjustment65 for the specified primary non-parametric comparisons: between 
unvaccinated and vaccinated TB Study 1 groups, and separately between BCG-only and other vaccinated 
groups. For TB Study 2, we similarly applied Holm-adjustment within groups of comparisons between 
unvaccinated and vaccinated TB Study 2 groups individually, and between the original 68-1 9Ag vector 
and the two modifications (68-1 6Ag, and 68-1.2 9Ag). Boxplots show unadjusted p-values; Holm-
adjusted p-values are shown in Supplementary Fig. 4. Vaccine-mediated protection is reported as 100%-
W, where W is 100 times the estimated rate (or confidence limit) of the Poisson or negative binomial 
model representing a count-valued outcome measure (necropsy score, necropsy culture, or the scaled 
combination outcome measure) among a vaccine group, as a fraction of the rate for unvaccinated RM. For 
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analysis of correlations across outcome variables, we used Spearman’s rank-transformed correlation 
statistic (r) and test. For Spearman’s test, p-values were computed via the asymptotic t approximation 
using the cor.test method in R. Binary comparisons of the dichotomous endpoint defined by any evidence 
of TB disease at necropsy were conducted using Fisher’s exact test, and confidence intervals for the 
dichotomous endpoint were estimated using Wilson’s score method66. 
T cell and antibody immunogenicity and immune correlates analysis. For comparisons of T cell 
immunogenicity across vaccine-receiving treatment groups at pre-challenge baseline, for comparisons of 
changes from baseline after challenge, and for comparisons of pre-challenge Ab responses across 
treatment groups, we first employed Kruskal-Wallis (KW) tests. The boxplots indicate significance of 
pairwise Wilcoxon tests if the KW test had a p-value ≤0.05 and the Wilcoxon test had a Holm-adjusted p-
value ≤0.05. Due to missingness of blood immunology data from week 41 of RM U6 (Study 1; BCG-only 
group), for Fig. 1d, n = 6 for the BCG group; and for Fig. 1c, the data point for this RM used only 2, 
rather than 3, time points for averaging. Due to missingness of immunology data of RM D1 and D2 
(Study 1; Unvaccinated group), n = 6 for the unvaccinated group. For analysis of immune response 
correlations with the scaled combination outcome measure (defined above) among RM receiving RhCMV 
and no BCG, we computed Spearman’s statistic and test, and in the scatterplots we also show the curve of 
the best-fitting negative binomial model. We confirmed through sensitivity analyses that the low 
correlations (Supplementary Fig. 10) were also found in each study separately and in each outcome 
measure, so the lack of significance is not an artifact of these analysis choices. Extensive non-parametric 
analyses as well as parametric analyses employing negative binomial models to estimate single-parameter 
and multi-parameter associations between this scaled combination measure and pre-challenge immune 
responses to RhCMV immunogens revealed no statistically supported ICS-determined T cell response 
magnitude correlate of that outcome, or of other related outcomes. 
 
Transcriptomic Analysis.   
RNA processing and sequencing. RM whole blood was drawn directly into PAXgene blood RNA tubes 
(PreAnalytiX, Hombrechtikon, Switzerland), which were stored at –20°C. RNA was extracted from 
PAXgene tubes according to the manufacturer’s instructions. Globin transcript depletion (GlobinClear, 
ThermoFisher Scientific, MA, USA) was performed on the extracted RNA, followed by cDNA library 
preparation using the Illumina TruSeq Stranded mRNA sample preparation kit (Illumina, CA, USA) for 
Study 1, and Eukaryote Transcriptome Library Construction Protocol (SOP-TRA J005, Beijing Genomics 
Institute, Shenzhen, China) for Study 2. For Study 1, globin transcript depletion, cDNA library 
preparation and RNA sequencing were performed by Expression Analysis/Q2 Solutions, Inc. (Durham, 
NC). For Study 2, these services were provided by Beijing Genomics Institute (Shenzhen, China). For 
Study 1, the sequencing strategy was 51bp paired-end reads at an average sequencing depth of 40M reads 
per sample. For Study 2, the sequencing strategy was 49bp paired-end reads at an average sequencing 
depth of 70M reads per sample.  RNA extraction failures for one Study 1 BCG group RM (U2), one Study 
1 68-1 RhCMV/TB group RM (N1), and four unvaccinated group RM (L1, L2, D1, and D2) precluded 
generation of RNA-Seq data for these animals, giving a total of 23 RM analyzed by RNA-Seq for Study 1 
(n=4 unvaccinated; n=6 RhCMV/TB vaccinated; n=6 BCG vaccinated, n=7 BCG+RhCMV/TB 
vaccinated). All 36 Study 2 RM were analyzed by RNA-Seq (n=9 for each group). For Study 1, RNA 
samples collected on the day of challenge and 14 and 28 days after challenge were analyzed by RNA-Seq. 
For Study 2, RNA samples collected prior to vaccination (for RhCMV/TB-vaccinated groups), on the day 
of challenge, and 28 days after challenge were analyzed by RNA-Seq.     
RNA-Seq data processing. Read pairs were preprocessed using scripts that adjust base calls with phred 
scores <5 to “N” and remove read pairs for which either end has fewer than 30 unambiguous (non-N) 
base calls. Processed read pairs were aligned using STAR (v.2.3.0.1)67 to the MacaM assembly68. Read 
pairs in which both ends mapped concordantly were used as input to the HTseq program69 (run in 
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stranded, intersection-strict mode) to assign gene counts. Of the 16,050 gene models, 11,977 and 12,517 
had at least 10 counts in at least 5% of the samples from Study 1 and 2, respectively, with 11,678 gene 
models meeting these criteria in both studies. Log2-transformed values of counts normalized by trimmed 
mean of M-values (TMM)70 adjusted library counts were computed for Study 1 and 2 using the 
calcNormFactors function of the edgeR package71 and the voom function of the package limma72. This 
widely-applied transformation seeks to normalize estimated gene expression levels for differences in both 
library size and overall transcriptome diversity and will help to minimize the effect of technical 
differences between samples or protocols between Study 1 and 2. 
Log2-transformed counts for Study 1 and 2 were then merged into a unified dataset that was used for all 
subsequent RNA-Seq-based correlates analyses. 
Identification of commonly regulated genes in TB patients and unvaccinated RM from Study 1 and 2 
after Mtb challenge. Normalized Illumina microarray data for HIV-uninfected South African and Malawi 
TB patients (n=46 from South Africa; n=51 from Malawi) and LTBI controls (n=48 from South Africa; 
n=35 from Malawi) from a previously published human TB study37 was down-loaded from the Gene 
Expression Omnibus along with the Entrez Gene annotations for the microarray platform. For cases where 
multiple probes targeted a common gene, the probe with the maximum 90% quantile of gene expression 
was selected. The human microarray and macaque RNA-Seq datasets were then matched in terms of gene 
symbols, yielding 10,075 genes that were assayed by both platforms. TB-associated genes in the human 
study were identified by two-sided Wilcoxon tests comparing TB patients to controls for the South 
African and Malawi sites. For each gene, the maximum Wilcoxon p-value for the two sites was false 
discovery rate (FDR)-adjusted for multiple comparisons using the Benjamini-Hochberg FDR adjustment 
procedure, after having first assigned p=1 for any genes with discordant patterns between the cohorts. The 
purpose of using the maximum p-value from the two sites as a summary statistic was to ensure that only 
genes were selected that were robustly and consistently associated with TB disease irrespective of any 
site-associated contributions of genetics or environment to transcriptional levels.  At a significance 
threshold of p<0.05 and FDR<0.33, 3406 TB-responsive genes were identified from the human study. 
These genes were then tested for responses in the unvaccinated RM from Study 1 (n=4) and Study 2 (n=9) 
by one-sided paired Wilcoxon tests comparing expression at 28 days post-challenge to pre-challenge 
levels, using the directionality from the response in humans. At a significance threshold of p<0.05 and 
FDR<0.33, 1482/3406 TB-responsive genes from the human study validated in the RM model, and 
median fold-changes were correlated between both systems (Fig. 5a-b; Supplementary Table 1).   
Identification of associations between transcriptional responses and outcome. Poisson regression 
modeling with sandwich adjustment, as described above (Necropsy score data), was used to test whether 
expression levels or expression fold-changes were significant predictors for outcome after challenge, as 
indicated by the scaled combination outcome measure. Briefly, Wald tests (R function: waldtest(); library: 
lmtest)73 with the regression coefficient covariance matrix being provided by heteroskedasticity-consistent 
covariance matrix estimation (R function: vcovHC(), library: sandwich62,63) were performed comparing 
two Poisson regression models that were generated for each gene: 
Model 1: outcome ~ gene + Study 
Model 2: outcome ~ Study 
(where: “outcome” = the scaled combination outcome measure, “gene” = log2 expression level or fold 
change for a specific gene, and “Study” = an additive factor with two levels: 0 or 1, with “0” 
corresponding to Study 1 and “1” corresponding to Study 2.)   
While the scaled combination outcome measure is harmonized between Study 1 and 2, minor technical 
differences between Study 1 and 2 RNA-Seq analysis (e.g. sequencing depth, library protocol, or service 
provider) may give rise to small shifts in expression between Study 1 and 2 that could confound the 
modeling.  Including the additive “Study” term in the model addresses this possible effect. Wald test p-
values from comparing Model 1 with Model 2 were FDR-adjusted for multiple comparisons using the 
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Benjamini-Hochberg procedure.  This overall strategy was applied to identify the post-challenge (Fig. 5) 
and pre-challenge (Fig. 6) transcriptional correlates with outcome as described below: 
Post-challenge correlates with outcome. When modeling outcome as a function of the log2 fold-change 
post challenge (day 28/day of challenge), data from all RM were included (all RhCMV/TB groups, BCG, 
and unvaccinated; n=59) from Study 1 and 2. To focus the analysis on the TB disease signature that is 
common between humans and RM, the set of genes analyzed was restricted to the 1482 TB-responsive 
genes that were discovered in the human TB cohort and validated in the unvaccinated RM (Fig. 5a). At 
the thresholds applied in the other analyses (p<0.05, FDR<0.33) a large number of significant associations 
were detected (1007 genes). For this reason, an additional filtering step was applied to focus the results on 
the strongest associations. Requiring that the absolute value of the overall Kendall tau rank correlation 
coefficient between the scaled combination outcome measure and gene expression fold-changes exceeded 
a value of 0.4 yielded the final set 214 genes shown in Fig. 5c (Supplementary Table 3).  
Pre-challenge correlates with outcome. When modeling outcome as a function of the log2 expression 
levels measured immediately before challenge, two analyses were performed: (i) using data from all RM 
that received RhCMV/TB vaccines (all RhCMV/TB groups and the BCG + RhCMV/TB group from 
Study 1; n=40), and (ii) using data from the unvaccinated and BCG (only) vaccine groups (n=19; Fig. 6a-
c). The objective of (i) was to identify pre-challenge correlates of eventual protection or susceptibility that 
were operational within the context of RhCMV/TB-induced immune responses (note that RhCMV/TB-
elicited Mtb-specific T cell responses were similar regardless of prior BCG vaccination; Fig. 1b-f). The 
objective of (ii) was to confirm that the associations in (i) were restricted to the context of RhCMV/TB 
vaccination and less likely to be due to monkey-intrinsic differences. Prior to Poisson regression, the 
average pre-challenge log2 expression levels for the unvaccinated RM was subtracted from the pre-
challenge log2 expression levels of all RM within the same study. 
For the RhCMV/TB-focused analysis (i), the complete transcriptome (11,678 genes) was analyzed. At the 
thresholds applied in the other analyses (p<0.05, FDR<0.33), 475 genes with significant associations were 
identified. This initial set was reduced to 315 genes by requiring that the sign of the Kendall tau rank 
correlation coefficient between gene expression and outcome be consistent for Study 1 and Study 2 
(different correlation signs could arise from the difference in sample number between Study 1 and Study 
2; requiring consistent directionality penalizes associations driven predominantly by Study 2 in favor of 
shared associations). We note that genes with overall negative correlations with outcome exhibited much 
greater sign consistency between Study 1 and Study 2 than genes with overall positive correlations with 
outcome (94/107 consistent genes negatively correlated with outcome; 221/368 consistent genes 
positively correlated with outcome).  The genes with the strongest associations between log2 expression 
and outcome were then identified by ranking the absolute value of the overall Kendall tau rank correlation 
coefficient between the scaled combination outcome measure and log2 gene expression levels (using 
“study adjusted” values for genes with nominally significant study terms – defined below).  Requiring the 
absolute value of the Kendall tau coefficient to exceed 0.2 yielded a set of 280 genes for subsequent 
analysis. All arbitrary thresholds including this Kendall tau threshold were determined once and held 
fixed thereafter to ensure interpretability of resulting statistics. To determine whether these candidate 
signatures were potentially driven by the RhCMV/TB vaccine, we tested whether these genes exhibited 
significant associations with outcome for the BCG and unvaccinated groups by Poisson modeling as 
described above. Of the 280 genes, 7 were nominally significant (p<0.05) and 22 exhibited p<0.2, 
indicating an overall absence of evidence for an association between the expression of the gene set and 
outcome for RM that did not receive RhCMV/TB vaccination. The 22 genes with p<0.2 for analysis (ii) 
were excluded, yielding the 258 genes shown in Figure 6a (Supplementary Table 5). Of these, 181 
exhibited pre-challenge expression levels that were positively correlated with values of the scaled 
combination outcome measure and were termed the “susceptibility signature,” meaning that higher 
expression of these genes prior to Mtb exposure was associated with a tendency to ultimately develop 
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more severe disease. Seventy-seven of the 258 genes exhibited pre-challenge expression levels that were 
negatively correlated with values of the scaled combination outcome measure and were termed the 
“protection signature,” meaning that higher expression of these genes prior to Mtb exposure was 
associated with a tendency to ultimately develop less severe disease or even complete protection. 
As described in the Results, inspection of the heatmap visualizations of protection and susceptibility 
signatures (Fig. 6a-b) suggested that the association between pre-challenge expression levels and 
outcome was predominantly binary, with strongly protected RMs exhibiting a distinct expression pattern 
compared to all other RM. This conjecture was explored by logistic regression modeling in which the 
scaled combination outcome measure was discretized into two levels: “completely protected” (14 RM that 
exhibited no signs of disease), and “non-protected” (all other RM that received RhCMV/TB vaccine). The 
modeling was essentially as above, replacing non-negative discrete numeric “outcome” with binary 
“protection”, and employing Chi-squared tests to compare models in lieu of the Wald test.  Also, instead 
of performing the modeling by including a “Study” term (Model 1 and Model 2), the “Study” term was 
removed and the modeling was performed using the “study adjusted” expression values for instances 
where the “Study” term was statistically significant based on the full Poisson models (Model 1 and Model 
2).  This is because there was only one protected RM in Study 1, and it is therefore not possible to reliably 
estimate a “Study” term for the logistic regression models. In addition to evaluating the statistical 
significance of the binary models, discriminatory potential of the models was evaluated using receiver 
operating curve (ROC) metrics (R package: pROC) to assess ROC AUC and stratified accuracy for Study 
1 and 2 at the optimal ROC operating point.  As described, results of this analysis supported the binary 
interpretation of the signatures, with 49% and 39% of protection and susceptibility genes, respectively, 
exhibiting “reasonable discriminatory ability” (Supplementary Table 5), which we defined as p<0.05, 
ROC AUC lower 95% confidence interval >0.5, and having a ROC operating point that simultaneously 
achieves at least 50% sensitivity and specificity in both Study 1 and Study 2.  
Heatmap visualizations. Heatmap visualizations were generated in R using the pheatmap library. 
Post-challenge correlates with outcome. The “Study” term in Model 1 was not nominally significant for 
any of the 214 genes identified (i.e., p>0.05), and for this reason, the log2 fold-change data shown in Fig. 
5c-e is presented without any additional transformations beyond the overall scaling for the heatmaps 
(dividing the values for each gene by the maximum absolute fold-change observed for that gene).  
Pre-challenge correlates with outcome. The “Study” term in Model 1 was nominally significant for about 
½ of the genes identified, indicating small differences in pre-challenge gene expression that did not 
influence associations with outcome but complicate visualizations. For these genes, “study adjusted” log2 
expression profiles were computed by adding to Study 2 log2 expression levels the estimate of the 
“Study” coefficient divided by the estimate of the “gene” coefficient from Model 1. This transformation 
aligns the Study 1 and 2 log2 expression levels to a common trajectory and facilitates visualization of the 
associations with outcome identified by the modeling. In the heatmaps, log2 expression profiles or “study 
adjusted” log2 expression profiles are shown after scaling the values for each gene by the maximum 
absolute fold-change observed for that gene.  
Module and pathway enrichment analysis. Fisher’s exact test was employed to determine whether genes 
belonging to pre-defined transcriptional modules or immune pathways were significantly over-represented 
within sets of genes that were identified as associated with outcome or other characteristics.  This analysis 
utilized two external sources for association of specific genes with transcriptional modules or pathways.  
The first was the set of blood transcriptional co-expression modules defined by Obermoser, et al53. These 
modules are advantageous because they define sets of similarly annotated genes that exhibit concordant 
expression patterns across an extensive set of immune-related blood transcriptional profiles.  Enrichment 
analysis of these modules was restricted to the annotated modules, and modules with common annotations 
were merged.  Definition and annotation of the modules is provided at: 
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http://www.biir.net/public_wikis/module_annotation/G2_Trial_8_Modules. The transcriptional modules 
were complemented by curated pathway definitions from Reactome54, which are not based on co-
expression, but rather extensive signaling pathway knowledge from the literature.  Enrichment analysis of 
these pathways was restricted to those within the “Immune System” branch of the overall hierarchy.  Each 
enrichment analysis required a “reference” gene set that constitutes the relevant compendium of candidate 
genes from which the gene set of interest was derived. The reference gene sets for each enrichment 
analysis are defined below. To exclude spurious enrichment results, modules and pathways with fewer 
than 50 members within the reference gene set were excluded. Gene sets for enrichment analysis were 
defined according to the association of interest and directionality (i.e., up-regulated genes were tested for 
module and pathway over-representation separately from down-regulated genes). Multiple comparisons 
were addressed by performing the Benjamini-Hochberg adjustment to the Fisher’s exact test p-values, 
with p-values for gene sets derived from a common analysis but exhibiting opposite directionality being 
adjusted together. Enrichment significance thresholds were set at p<0.05 and FDR<0.15. 
Enrichment analysis of TB-responsive genes in humans and RM (Fig. 5b and Supplementary Table 2). 
The reference gene sets were the 10,075 genes commonly detected in the human and NHP platforms and 
the gene sets of interest were the 793 up- and 689 down-regulated genes from the 1482 genes regulated in 
common. Enriched modules and pathways with fewer than 20 members within the up- and down-
regulated genes are not shown. 
Enrichment analysis of TB-responsive genes with post-challenge fold-changes associated with outcome in 
RM (Figs. 5c-d and Supplementary Table 4). The reference gene sets were the 1482 genes regulated in 
common between human and NHP and the gene sets of interest were the 196 genes positively associated 
and 18 genes negatively associated from the 214 with post-challenge fold-changes associated with 
outcome.  Enriched modules and pathways with fewer than 2 members within the positively- and 
negatively-associated genes are not shown. 
Enrichment analysis of genes with pre-challenge expression profiles that are associated with outcome in 
RhCMV/TB-vaccinated RM (Fig. 6a-b and Supplementary Table 6). The reference gene sets were the 
11,678 genes detected in common between Study 1 and 2 and the gene sets of interest were the 181 genes 
positively associated (susceptibility signature) and 77 genes negatively associated (protection signature) 
from the 258 with pre-challenge expression profiles associated with outcome. Enriched modules and 
pathways with <2 members within the positively- and negatively-associated genes are not shown. 
Integration of transcriptional measurements with leukocyte population counts. To gain insight into the 
contribution of leukocyte trafficking to the pre-challenge protection and susceptibility signatures, we 
integrated the transcriptome data with whole blood leukocyte percentages. Bulk lymphocyte, monocyte, 
and neutrophil population percentages in whole blood on the day of challenge were determined by Coulter 
Counter (Study 1) and Horiba blood cell counter (Study 2). Basophil and eosinophil counts were excluded 
because they were marginal in both studies and not likely to contribute to the whole blood transcriptome 
readouts. The contribution of T cells (CD3+) and T cell subsets (CD4+, CD8+) to the bulk lymphocyte 
count was further determined for Study 1 and 2 by flow cytometry. Leukocyte counts were utilized in 
three exploratory analyses: (i) testing leukocyte populations themselves for pre-challenge associations 
with outcome, (ii) identifying the leukocyte population most associated with specific genes, and (iii) 
determining whether leukocyte population differences may be responsible for the pre-challenge 
transcriptional associations with outcome. Both untransformed and log10-transformed leukocyte % were 
investigated in the exploratory analyses. 
Testing leukocyte populations alone for pre-challenge associations with outcome: In this analysis, the 
Poisson regression analysis (described above) for identifying pre-challenge transcriptional correlates with 
outcome was repeated exactly, but substituting leukocyte population counts (and log transformations 
thereof) for genes. No single leukocyte population, nor ratios between monocytes and lymphocytes, 
neutrophils to lymphocytes, or neutrophils to monocytes, achieved nominally significant associations with 
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outcome (i.e., p>0.05 for all populations) or nominally significant Kendall rank correlations with outcome 
(i.e., p>0.05 for all populations). 
Identifying the leukocyte population most associated with specific genes: Given the non-transitive nature 
of correlations, it is possible that genes that are significantly associated with outcome may be significantly 
associated with certain leukocyte populations, even if those leukocyte populations themselves are not 
significantly associated with outcome. This scenario could arise, for example, if the activation state of a 
certain leukocyte subpopulation, as indicated by expression of a specific gene set, was associated with 
outcome.  We determined the leukocyte population associated with each gene by performing robust linear 
regression (R: rlm, package: MASS) using the following model structure: 
Model 3: Cell ~ gene + Study 
(where “Cell” = the leukocyte population percentage of interest (neutrophils, monocytes, lymphocytes, 
T cells, CD4+ T cells, or CD8+ T cells and log transformations thereof), and “gene” and “Study” are as 
defined above). 
As the focus of the analysis was for the interpretation of the pre-challenge protection and susceptibility 
signatures (Fig. 6a), robust linear regression modeling was restricted to leukocyte counts and 
transcriptome data for RM that received RhCMV/TB vaccination.  The significance of the association 
between the gene and leukocyte population was determined by robust F-tests on the “gene” coefficient 
from the model (R: f.robftest, package: sfsmisc). Plausible leukocyte/cell associations were defined as 
those for which the model coefficient was nominally significant (p<0.05) and the coefficient was positive 
(indicating a positive relationship between transcription and the cells). Of the genes with more than one 
plausible association meeting these criteria, the cell population with the smallest p-value was selected. 
To determine whether genes with plausible associations with specific leukocyte populations were over-
represented in the pre-challenge protection or susceptibility signatures, Fisher’s exact tests were 
performed as described above, except replacing the transcriptional module and pathway annotations with 
the associations between genes and cell populations. Given the hierarchical relationship between CD4+ 
and CD8+ T cells, T cells, and lymphocytes, genes/lymphocyte associations detected lower in the 
hierarchy were also assigned to upper branches of the hierarchy (i.e., a gene associated with CD4+ T cells 
would also be counted as a gene associated with T cells and lymphocytes). Similarly, genes most 
associated with actual CD4+ T cell percentages or log-transformed CD4+ T cell percentages were simply 
regarded as “CD4+ T cell-associated.” The full list of gene by leukocyte populations is provided in 
Supplementary Table 7.  Enrichment results for association with leukocyte populations are provided in 
Supplementary Table 8. 
Determining whether leukocyte population differences may be responsible for the pre-challenge 
transcriptional associations with outcome: Additional Poisson regression analyses were performed to 
determine whether the association between pre-challenge expression of a certain gene and outcome were 
driven by the leukocyte population with which the gene was most associated. This followed the identical 
sandwich-adjusted Poisson modeling and Wald test for model comparison as described above, except 
including new terms for the leukocyte population associated with the gene being tested: 
Model 4: outcome ~ gene + Cell + Study 
Model 5: outcome ~ Cell + Study 
(where: “Cell” = the leukocyte population most associated with the gene being analyzed, and “gene” 
and “Study” are as defined above).   
If variation in the leukocyte population was driving the association between outcome and the gene, then 
the gene would not contribute to the model fit and there would be no statistically significant difference 
revealed by the Wald test comparing Model 4 and Model 5.  As above, this analysis was performed only 
for RM that received RhCMV/TB vaccine, only at the pre-challenge time point, and only for those genes 
from the protection and susceptibility signatures (Fig. 6a) for which there was a plausibly associated 
leukocyte population.  Of the 280 genes, 82 were associated with at least one leukocyte population, and 
four of these (AMIGO1, DDX39B, GMEB2, and TYSND1, all from the susceptibility signature) lost 
Nature Medicine A88164-T (Revision) - 30 
nominal significance in the comparison between Model 4 and 5 (p ranged from 0.05 to 0.08 for these 
genes) (Supplementary Table 5). This result suggests that the protection and susceptibility signatures do 
not likely result from nor are driven by trafficking differences in bulk leukocyte populations. 
Testing for differences between RhCMV/TB and BCG + RhCMV/TB pre-challenge transcriptional 
patterns.  One-sided Wilcoxon rank-sum tests were performed to compare the expression levels of genes 
from the protection signature in the RhCMV/TB group (n=6) to the BCG + RhCMV/TB(n=7) group from 
Study 1. Given the tendency within the BCG + RhCMV/TB group towards reduced protection, we tested 
whether pre-challenge expression of the protection-associated genes was reduced in this group compared 
to the group that received RhCMV alone. At p<0.05 and FDR<0.33, 15 genes were identified that meet 
this criterion (Fig. 6d and Supplementary Table 9). 
 
DATA AND COMPUTER CODE AVAILABILITY 
The datasets generated and/or analyzed during the current study, as well as the computer code used to 
perform statistical analysis, are available from the corresponding authors on reasonable request. Raw and 
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Supplementary Figure 1: Description of RhCMV/TB vectors and analysis of Mtb-specific Abs in 
Study 1 and 2 RM. (a) Diagram shows the insertion sites for TB Ag cassettes in the RhCMV 68-1 and 
68-1.2 BAC backbones. The top 4 constructs use exogenous promoters (either MCMV IE or EF1a) to 
drive insert expression, whereas the bottom construct (68-1 RhCMV/TB-6Ag) replaces the Rh107 coding 
region with the 6 Ag insert, and relies upon the endogenous Rh107 promoter to regulate insert expression. 
(b,c) A customized Luminex assay (see Methods) was used to determine the levels of circulating IgG1 to 
each of the indicated TB insert Ags, whole PPD, and a non-Mtb control Ag (SIVgp120) at end-of-vaccine 
phase for n=27 Study 1 (b) and n=36 Study 2 (c) RM (Study 1: week 47; Study 2: week 52).  Ig isolated 
from n=5 RM with high titre anti-gp120 Abs (SIVIG) was used as a positive control (inset). Plots show 
jittered points with a box from 1st to 3rd quartiles (IQR) and a line at the median, with whiskers 
extending to the farthest data point within 1.5*IQR above and below the box respectively. The dotted gray 
lines indicate the cutoff for positivity for a vaccine-elicited Ab response based on using the median + 3 
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Supplementary Figure 2: Dynamics of de novo and boosted Mtb-specific CD8+ T cell responses after 
Mtb challenge. (a,c,d) Development of de novo peripheral blood CD8+ T cell responses after Mtb 
challenge to the peptide mixes comprising the non-vaccine insert Mtb protein CFP-10 in Study 1 (a) and 
Study 2 (c) RM, and to the peptide mixes comprising the Ag85B, Rv1733 and Rpf proteins in Study 2, 
group 3 RM (d), who received the RhCMV/TB-6Ag vaccine lacking these insert Ags. Responses were 
quantified by flow cytometric ICS analysis with the response defined by frequency of cells producing 
TNF- and/or IFN-g-producing cells after background subtraction in memory subset. Corresponding CFP-
10-specific and insert Ag-specific CD4+ T cell responses are shown in Figs. 2a and 4a,b. Note in these 
figures that all Mtb-challenged RM, including vaccinated RM that did not manifest post-challenge 
disease, showed multiple post-challenge samples with above-threshold CFP-10-specific CD4+ and CD8+ T 
cell responses. (b,e) Mean (+ SEM) change in peripheral blood CD8+ memory T cell response frequencies 
to peptide mixes comprising the vaccine insert Mtb proteins after Mtb challenge from pre-challenge 
baseline by flow cytometric ICS analysis (responses defined as above) in Study 1 (b; n=29) and Study 2 
(e; n=36) RM. Corresponding CD4+ T cell responses are shown in Figs. 2b and 4c). There were no 
significant differences in post-challenge change-from-baseline CD8+ T cell AUC between unvaccinated 
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Supplementary Figure 3: Pathologic scoring of TB disease at necropsy. The tables show the criteria 
and scoring system used to quantify the pathologic extent of TB disease at necropsy in Study 1 and 2 RM.  
Note that every RM receives a separate score for 7 lung lobes, chest wall, each separate LN group (both 
chest and non-chest), liver, spleen, and each other involved organ, with the sum of these scores being the 
overall Pathologic Score. The sum of the scores for the 7 lung lobes is the Lung (Pulmonary) Pathologic 
Score, with the sum of all other scores (including chest wall and LNs) being the Non-Lung (Extra-
Pulmonary) Pathologic Score. The sum of all scores (Lung and Non-Lung) is the Overall Pathologic 
Score.  
  











1 *Hilar, Carinal, Paratracheal, Internal Mammary; Other Mediastinal, Mesenteric or Peripheral  
**Scored only if LN was enlarged due to granulomatous inflamation.2
3




*Left Upper, Left Middle, Left Lower; Right Upper, Right Middle; Right Lower; Right Accessory 2
**an additional point is scored for each of the following: 1) cavitation of 1 or more granulomas,  3
2) granulomatous involvement of the trachea or large bronchi resulting in perforation. 3) pleura  4
thickening, and 4) pleural adhesions (max 1 point per RM for each).
0















3 *Kidney, Bladder, Pancreas, Small Bowel, Large Bowel>4 mm 
Granuloma Size
No granulomas
Focal or Multifocal, <2mm, not miliary or confluent
Coalescing involving <50% of lobe 
Complete granulomatous effacement
Lymph Node Size
 No granulomatous involvement
Nodes visibly enlarged (5-10 mm) unilateral 
Nodes visibly enlarged (5-10 mm) bilateral 
Nodes visibly enlarged** (>1 cm) unilateral/bilateral 






Coalescing involving >50% of lobe (but without effacement)
Granulomatous disease not present 
Granulomatous disease present; all lesions <1cm
Granulomatous disease present; one or more lesions >1cm
Granuloma Number
>20mm, not miliary or confluent
Confluent or miliary lesions involving <50% of lobe 












































Supplementary Figure 4: Summary of outcome statistics. (a,b) Study 1 analysis. (c,d) Study 2 
analysis. (e) Combined analysis (see Methods for description of statistical approaches).  




Study 1 estimated Vaccine Effect (VE) to reduce the rate of each outcome measure, using a negative
binomial (Poisson) model:
Study 2 estimated Vaccine Effect (VE) to reduce the rate of each outcome measure, using a negative
binomial (Poisson) model:















0.5358 0.0818 0.0919 0.4491 0.1473 0.1046 0.1206
0.5619 0.0818 0.1447 0.4491 0.2946 0.1046 0.2412
0.0093 0.0031 0.0148 0.0064 0.0045 0.0026 0.0065
0.0280 0.0092 0.0445 0.0192 0.0136 0.0077 0.0195
0.2810 0.0317 0.0723 0.0314 0.2950 0.0077 0.1893
0.5619 0.0633 0.1447 0.0627 0.2950 0.0153 0.2412
0.0728 0.1223 0.2475 0.0083 0.0103 0.0247 0.0250
0.1457 0.2446 0.4951 0.0166 0.0207 0.0494 0.0501
0.6200 0.7961 1.0000 0.0628 0.8979 0.2003 0.7104
0.6200 0.7961 1.0000 0.0628 0.8979 0.2003 0.7104



















































OutcomeGroup A Group B Estimated VE 2.50% 97.50% P value




68.71% 49.58% 80.61% <0.0001
Necropsy Score - Overall
Necropsy Culture - Overall







Study 2 Vaccine Effect by Group*:
Group A
Unvaccinated
0.2116 0.0524 0.0727 0.0032 0.0074 0.0162 0.0321
0.2116 0.0551 0.0727 0.0065 0.0169 0.0162 0.0643
0.0057 0.0276 0.0173 0.0022 0.0056 0.0026 0.0064
0.0170 0.0551 0.0347 0.0065 0.0169 0.0077 0.0193
0.0214 0.0009 0.0098 0.0118 0.1435 0.0031 0.1011
0.0428 0.0027 0.0295 0.0118 0.1435 0.0077 0.1011
68-1
RhCMV/TB-6Ag (n=9)
0.5939 1.0000 0.8842 0.9261 0.8462 0.9271 0.8844
1.0000 1.0000 1.0000 1.0000 0.8462 1.0000 1.0000
1.0000 0.5110 0.9259 0.5812 0.3798 0.8810 0.5479
1.0000 1.0000 1.0000 1.0000 0.7596 1.0000 1.0000
0.0071 0.0012 0.0041 0.0003 0.0033 0.0004 0.0056
Outcome Estimated VE P value
Necropsy Culture - Overall 74.48% 0.0024







**Necropsy Mtb culture data was not available for 1 RM in this group, resulting in n = 8 for comparisons involving these culture data.
**Necropsy Mtb culture data was not available for 1 RM in this group, resulting in n = 26 for comparisons involving these culture data.
Group B
e Overall (Study 1 + Study 2) estimated Vaccine Effect (VE) to reduce the rate of the scaled, combined




With TB Disease (n=20)**
Group A
Unvaccinated
**necropsy pathologic score ≥ 4 (excluding RM with necropsy pathologic = 0).













*Unadjusted p-values of the pairwise, two-sided Wilcoxon tests across groups with Holm-adjusted p-values in italics and all p-values ≤ 0.05 in bold. 
Holm adjustments are made separately for each outcome measure (column), together for results sharing a common Group A value.  Thus, the three 
comparisons of the unvaccinated vs. the vaccinated groups are adjusted together because they address a common hypothesis, and these are conduct-
ed separately from the Holm adjustment of the comparisons of the BCG-only group to the other vaccines.  The final comparison across the two regimens 
including 68-1 RhCMV/TB with or without BCG receive no adjustment. 
*Unadjusted p-values of the pairwise, two-sided Wilcoxon tests across groups with Holm-adjusted p-values in italics and all p-values ≤ 0.05 in bold. 
Holm adjustments are made separately for each outcome measure (column), together for results sharing a common Group A value. Thus, the three 
comparisons of the unvaccinated vs. the vaccine groups are adjusted together because they address a common hypothesis, and these are conducted 
separately from the Holm adjustment of the comparisons of the original 68-1 RhCMV/TB-9Ag vector group to the other vaccines.  The final comparison 
between the unvaccinated and the All RhCMV/TB vector-vaccinated RM receives no adjustment. 























Supplementary Figure 5: Assessment of TB infection outcome. (a) Correlation of pulmonary 
parenchymal disease as measured by CT scan-determined disease volume (AUC through day 112 post-
infection) vs. lung pathologic score (left panel) and Mtb culture of lung samples (right panel) at necropsy 
for Study 1 RM (n=29). (b) Correlation of overall Mtb culture vs. overall pathologic score at necropsy of 
Study 1 RM (n=29). (c,d) Same analysis for Study 2 RM (n=35, 36, 35, respectively). Spearman 
correlation coefficients (r) and associated p-values are shown in each plot. Note that the single point at the 
origin (0,0) reflects 13 RM in c, and 10 RM in d. In addition, the (0,1) point in d reflects super-imposition 
of 2 RM. (e,f) Boxplots compare the extent of Mtb infection in lung-draining LNs (hilar, carinal, 
paratracheal) at necropsy as measured by the density of Mtb (CFU; determined by quantitative 
mycobacterial culture) per gram of tissue for RM groups in Study 1 (e; n=29) and Study 2 (f; n=35). In e 
and f, plots show jittered points with a box from 1st to 3rd quartiles (IQR) and a line at the median, with 
whiskers extending to the farthest data point within 1.5*IQR above and below the box respectively; 
unadjusted two-sided Wilcoxon p-values ≤0.05 are also shown. Of note, the lung-draining LN CFU/gram 
outcome measure was highly correlated with other outcome measures (CT AUC Pearson’s r = 0.68, 
overall necropsy score r = 0.70, and overall necropsy Mtb culture 0.72), and it was especially highly 


































Supplementary Figure 6: Summary of TB disease outcome at necropsy of Study 1. The lung, non-
lung, and overall extent of Mtb disease by Mtb culture (# positive cultures; left y-axis) and pathologic 
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Supplementary Figure 7: MHC restriction analysis of RhCMV/TB-elicited CD8+ T cell responses in 
Study 2. RhCMV/TB-elicited CD8+ T cells were epitope-mapped in the indicated group 1, 2, and 3 RM 
from Study 2 using flow cytometric ICS assay to detect recognition of each consecutive, overlapping 
15mer gag peptide comprising the indicated TB proteins. Peptides resulting in specific CD8+ T cell 
responses are indicated by a box, with the color of the box designating MHC restriction as determined by 
blocking with the anti-pan-MHC-I mAb W6/32, the MHC-E blocking peptide VL9 and the MHC-II 
blocking peptide CLIP as previously described25. The epitope restriction profiles of the strain 68-1 
RhCMV/Ag85B/ESAT-6- and RhCMV/Rpf A/Rpf C/Rpf D-elicited CD8+ responses to Rpf A, Ag85B, 
and ESAT-6 have been previously published25, but are reproduced here for comparison with 68-1.2 
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Supplementary Figure 8: Analysis of non-vaccine-elicited, Mtb-specific CD4+ and CD8+ T cell 
responses at necropsy (response to Mtb challenge). (a) Flow cytometric ICS analysis demonstrating 
peripheral blood and tissue CD4+ and CD8+ T cell responses to the peptide mixes comprising the non-
vaccine insert Mtb protein CFP-10 in the one Study 1 RM and the 13 Study 2 RM (n=5, 3, and 5 from 
Groups 1, 2 and 3, respectively) without pathologic evidence of TB disease at necropsy (see 
Supplementary Figs. 6 and 9; response defined by TNF and/or IFN-g production after background 
subtraction in memory subset). (b) Similar analysis of T cell responses to peptide mixes comprising the 
Ag85B, Rv1733 and Rpf proteins in the five Study 2, group 3 RM (vaccinated with the RhCMV/TB-6 Ag 
vaccine lacking these inserts) who failed to manifest TB disease after challenge. These data confirm that 
these protected monkeys were sufficiently exposed to Mtb infection after challenge to develop a robust 
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68-1 RhCMV/TB-9Ag (Group 1)
68-1 RhCMV/TB (Study 1)

































































































68-1 RhCMV/TB-6Ag (Group 3)
68-1 RhCMV/TB-6Ag
 
Supplementary Figure 9: Summary of outcome at necropsy of Study 2. The lung, non-lung, and 
overall extent of Mtb disease by Mtb culture (# positive cultures; left y-axis) and pathologic scoring (right 




































Culture Nx Score Culture Nx Score Culture Nx Score Culture Nx Score Culture Nx Score
68-1.2 RhCMV/TB-9Ag
Culture Nx Score Culture Nx Score Culture Nx Score Culture Nx Score Culture Nx Score
68-1 RhCMV/TB-9Ag
Culture Nx Score Culture Nx Score Culture Nx Score Culture Nx Score Culture Nx Score
68-1 RhCMV/TB-6Ag



































































































































































































































































































































































































 Supplementary Figure 10: Immune correlates analysis. (a,b) The relationship between the end-of-
vaccine phase, overall Mtb-specific CD4+ and CD8+ T cell responses in peripheral blood (a) and BAL (b) 
to the scaled outcome measure that combines both Mtb culture and pathologic score data at necropsy (see 
Methods) is shown for all Study 1 and 2 RM (n=41) that received a RhCMV/TB vaccine (with or without 
BCG). The T cell responses reflect the sum of responses to the 9 TB insert Ags and are presented in units 
of z-score (number of standard deviations that a RM’s normalized total immune response is above the 
average of the RM in that study, see Methods). (c) The same analysis is shown for overall Mtb-specific 
CD4+ and CD8+ T cell responses in peripheral LN in RhCMV/TB-vaccinated Study 2 RM (LN biopsy 
was not performed in Study 1). Spearman correlation coefficients (r) and associated p-values are shown in 
each plot, with the best-fitting negative binomial curve overlaid. Similar lack of significant correlation 
was observed for total AUC CD4+ or CD8+ T cell responses for the entire vaccine phase in peripheral 
blood, and for peripheral blood, BAL, and peripheral LN responses to only the 6 Ags common to all 
RhCMV/TB-vaccinated RM, or to any individual Mtb Ag prior to challenge. (d,e) Post-challenge mean (+ 
SEM) change-from-baseline of the CD4+ and CD8+ T cell response to each of the indicated TB Ags in 
Study 2 RM comparing the unvaccinated group (group 4; n=9) with vaccinated RM that were either 
completely protected (e.g., n=13 RM from groups 1-3 with no granulomatous disease at necropsy; 
necropsy disease score = 0) or not completely protected (e.g., n=14 RM from groups 1-3 with necropsy 
disease score ≥4; see Supplementary Fig. 9).  Note that these are the same data shown in Fig. 4c, but 
with vaccine groups reconfigured to reflect outcome. Holm-adjusted, two-sided Wilcoxon p-values ≤0.05 
are shown in red for change-from-baseline AUC of post-challenge responses in the vaccinated group 
without disease (red lines) that were significantly different from that of the vaccinated group with TB 
disease (black lines; note that only CD4+ T cell responses to ESAT-6 and CFP-10 achieved significance 
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Supplementary Table Legends 
 
Supplementary Table 1: 1482 Genes comparably regulated in TB patients and unvaccinated RM 
from Study 1 and 2 after Mtb challenge. Normalized Illumina microarray data for HIV-uninfected 
South African and Malawi TB patients (South Africa: n=46, Malawi: n=51) and LTBI controls (South 
Africa: n=48, Malawi: n=35) was down-loaded from the Gene Expression Omnibus (GSE37250) and 
used to define a robust set of 3406 TB-responsive genes.  These genes were then tested for responses in 
the unvaccinated RM from Study 1 (n=4) and 2 (n=9) by one-sided paired Wilcoxon tests comparing 
expression at 28 days post-challenge to pre-challenge levels, using the directionality from the response in 
humans.  This table contains the following values for each human cohort: p (two-sided Wilcoxon) and 
Median Log2 FC, comparing TB cases to LTBI controls.  The summary statistics for the human cohorts 
are: MAX (p (two-sided Wilcoxon)), AVERAGE (Median Log2 FC), and FDR.  For the unvaccinated RM, 
the following values are provided: p (one-sided paired Wilcoxon), Median Log2 FC, and FDR. 
 
Supplementary Table 2: Pathway enrichments for genes comparably regulated in TB patients and 
unvaccinated RM from Study 1 and 2 after Mtb challenge. This table provides statistics for pathway 
enrichment analysis of TB-responsive genes that were identified in humans and confirmed in Mtb-
challenged RM (Supplementary Table 1). For the enrichment analysis, the reference gene set was the 
10,075 genes commonly detected in the human and NHP platforms and the gene sets of interest were the 
793 up- and 689 down-regulated genes from the 1482 genes regulated in common. Enriched modules and 
pathways with fewer than 20 members within the up- and down-regulated genes are not shown.  For both 
the 793 genes that are up-regulated in TB vs. LTBI and after Mtb challenge in RM and the 689 genes that 
are down-regulated in TB vs. LTBI and after Mtb challenge in RM, the following values are provided for 
each enriched module or pathway: # of genes in reference = number of genes in the reference gene set 
annotated to that module or pathway, # of genes in gene set of interest = number of genes in the gene set 
annotated to that module or pathway, p (one-sided Fisher's Exact Test), and FDR. 
 
Supplementary Table 3: 214 genes with post-challenge expression patterns in vaccinated and 
unvaccinated RM that are highly significantly associated with scaled combination outcome 
measure. The scaled combined outcome measure was modeled as a function of the log2 fold-change post 
challenge (day 28/day of challenge) using data from all RM from Study 1 and Study 2 (all RhCMV/TB 
groups, BCG, and unvaccinated; n=59). The set of genes analyzed was restricted to the 1482 TB-
responsive genes that were discovered in the human TB cohort and validated in the unvaccinated RM.  At 
the thresholds applied in the other analyses (p<0.05, FDR<0.33) a large number of significant associations 
were detected (1007 genes) and therefore an additional filtering step was applied to focus the results on 
the strongest associations by requiring that the absolute value of the overall Kendall tau rank correlation 
coefficient between the scaled combination outcome measure and gene expression fold-changes exceeded 
a value of 0.4.  For each gene, the following values are provided: pPoisson (Model 1 vs. Model 2) = p-
value from Wald test comparing Poisson regression models with and without "gene" term (see Methods), 
FDR = Benjamini-Hochberg adjusted pPoisson (Model 1 vs. Model 2), pStudy = p-value from Wald test 
comparing Model 1 to a variation without the "Study" term, Kendall Tau = Kendall Tau rank correlation 
coefficient for association between gene expression fold-changes and the scaled combined outcome 
measure evaluated using Study 1 or Study 2 alone or combined. 
 
Supplementary Table 4:  Pathway enrichments for genes with post-challenge expression patterns 
that are highly significantly associated with scaled combination outcome measure. This table 
provides enrichment analysis results for TB-responsive genes with post-challenge fold-changes that were 
associated with outcome in RM. The reference gene set was the 1482 genes regulated in common between 
human and NHP and the gene sets of interest were the 196 genes positively associated and 18 genes 
 
negatively associated from the 214 with post-challenge fold-changes associated with outcome 
(Supplementary Table 3).  Enriched modules and pathways with fewer than 2 members within the 
positively- and negatively-associated genes are not shown.  Significant results were only obtained for the 
196 genes with Day 28 post-challenge/pre-challenge fold-changes that are positively associated with the 
scaled combined outcome measure.  The following values are provided for each enriched module or 
pathway: # of genes in reference = number of genes in the reference gene set annotated to that module or 
pathway, # of genes in gene set of interest = number of genes in the gene set annotated to that module or 
pathway, p (one-sided Fisher's Exact Test), and FDR. 
 
Supplementary Table 5: 258 genes with pre-challenge expression patterns in RhCMV-vaccinated 
RM that are significantly associated with the scaled combination outcome measure. The scaled 
combined outcome measure was modeled as a function of the log2 expression levels measured 
immediately before challenge using the following combined subgroups of RM from Study 1 and Study 2: 
(i) all RM that received RhCMV/TB vaccines (all RhCMV/TB groups and the BCG + RhCMV/TB group 
from Study 1; n=40), and (ii) RM that were unvaccinated or solely received BCG vaccination (n=19).  For 
the RhCMV/TB-focused analysis (i), the complete transcriptome (11,678 genes) was analyzed. At the 
same thresholds applied in the other analyses (p<0.05, FDR<0.33), 475 genes with significant 
associations were identified. This initial set was reduced to 315 genes by requiring that the sign of the 
Kendall tau rank correlation coefficient between gene expression and outcome be consistent for Study 1 
and Study 2. Genes with the strongest associations between log2 expression and outcome were then 
identified by ranking the absolute value of the overall Kendall tau rank correlation coefficient between the 
scaled combination outcome measure and log2 gene expression levels (using “study adjusted” values for 
genes with nominally significant study terms; see Methods).  Requiring the absolute value of the Kendall 
tau coefficient to exceed 0.2 yielded a set of 280 genes. To determine whether these candidate signatures 
were potentially driven by the RhCMV/TB vaccine, we tested whether these genes exhibited significant 
associations with outcome for the BCG and unvaccinated groups (ii, defined above) by Poisson modeling. 
Of the 280 genes, 7 were nominally significant (p<0.05) and 22 exhibited p<0.2, indicating an overall 
absence of evidence for an association between the expression of the gene set and outcome for RM that 
did not receive RhCMV/TB vaccination, yielding the 258 genes in this table.  Of these, 181 exhibited pre-
challenge expression levels that were positively correlated with values of the scaled combination outcome 
measure and were termed the “susceptibility signature,” meaning that higher expression of these genes 
prior to Mtb exposure was associated with a tendency to ultimately develop more severe disease. Seventy-
seven of the 258 genes exhibited pre-challenge expression levels that were negatively correlated with 
values of the scaled combination outcome measure and were termed the “protection signature,” meaning 
that higher expression of these genes prior to Mtb exposure was associated with a tendency to ultimately 
develop less severe disease or even complete protection. For both the susceptibility signature and 
protection signature genes, the following values are provided:  pPoisson (Model 1 vs. Model 2) = p-value 
from Wald test comparing Poission regression models with (Model 1) and without "gene" term (Model 2) 
(see Methods), FDR = Benjamini-Hochberg adjusted pPoisson (Model 1 vs. Model 2),  pStudy = p-
value from Wald test comparing Model 1 to a variation without the "Study" term, Coefficient for 
adjusting Study 2 = Value which is added to Study 2 expression values prior to visualization and 
computation of the overall Kendall tau correlation for Study 1 + Study 2 when pStudy is nominally 
significant, Kendall Tau = Kendall’s tau rank correlation coefficient for association between gene 
expression fold-changes and the scaled combined outcome measure evaluated using Study 1 or Study 2 
individually or combined, pBinary = Chi-squared test p-value for comparing binomial (logistic regression 
models) for predicting protection as a function of the expression of the gene on the day of challenge, ROC 
AUC = Area under the curve (AUC) for the receiver operating characteristic (ROC) of the logistic 
regression model for the binary discretization of the outcome in terms of protected and non-protected RM, 
ROC AUC (lower CI) = Lower 95% confidence interval for ROC AUC, Sensitivity = The sensitivity for 
 
predicting protected RM based on the expression of the indicated gene using the logistic regression model 
at the optimal threshold on the ROC, Specificity = The specificity for predicting protected RM based on 
the expression of the indicated gene at the optimal threshold on the ROC, Associated leukocyte population 
= The specific leukocyte population that is most strongly (positively) associated with the indicated gene, p 
(Association between gene and cell type) = This is the robust F-test p-value for the "gene" coefficient in 
the robust linear regression model describing the leukocyte population percentage as a function of gene 
expression and Study (see Methods), pPoisson (Model 4 vs. Model 5) = p-value from Wald test comparing 
Poisson regression models with (Model 4) and without "gene" term (Model 5) while including terms for 
Study and the most strongly associated leukocyte population with the given gene (see Methods). 
 
Supplementary Table 6: Pathway enrichments for genes with pre-challenge expression patterns in 
RhCMV-vaccinated RM that are significantly associated with scaled combination outcome 
measure. This table provides enrichment analysis results for genes with pre-challenge expression profiles 
that are associated with outcome in RhCMV/TB-vaccinated RM. The reference gene set was the 11,678 
genes detected in common between Study 1 and 2 and the gene sets of interest were the 181 genes 
positively associated (susceptibility signature) and 77 genes negatively associated (protection signature) 
from the 258 with pre-challenge expression profiles associated with outcome. Enriched modules and 
pathways with <2 members within the positively- and negatively-associated genes are not shown.  The 
following values are provided for each enriched pathway or module for each gene set: # of genes in 
reference = number of genes in the reference gene set annotated to that module or pathway, # of genes in 
gene set of interest = number of genes in the gene set annotated to that module or pathway, p (one-sided 
Fisher's Exact Test), and FDR. 
 
Supplementary Table 7: Lists of genes exhibiting plausible associations with specific leukocyte 
populations for RhCMV/TB-vaccinated RM on the day of challenge.  This table provides statistics for 
the evaluation of associations between leukocyte populations and the expression of each detected gene 
using robust linear regression (see Methods).  For each gene, the following values are provided: 
Associated leukocyte population =The specific leukocyte population that is most strongly (positively) 
associated with the indicated gene, Associated leukocyte population (nice label) = Same as in column B, 
except the actual and log-transformed cell populations are now combined and this is the annotation label 
that was used in the cell population enrichments (Supplemental Table 8), p (Association between gene 
and cell type) = This is the robust F-test p-value for the "gene" coefficient in the robust linear regression 
model describing the leukocyte population percentage as a function of gene expression and Study (see 
Methods). 
       
Supplementary Table 8: Cell population enrichments for genes with pre-challenge expression 
patterns in RhCMV-vaccinated RM that are significantly associated with scaled combination 
outcome measure. Analogously to Supplementary Table 6, this table provides enrichment analysis 
results evaluating whether genes with plausible associations with specific leukocyte populations 
(Supplementary Table 7) were over-represented in the pre-challenge protection and susceptibility 
signatures.  Given the hierarchical relationship between CD4+ and CD8+ T cells, T cells, and 
lymphocytes, genes/lymphocyte associations detected lower in the hierarchy were also assigned to upper 
branches of the hierarchy (i.e., a gene associated with CD4+ T cells would also be counted as a gene 
associated with T cells and lymphocytes). Similarly, genes most associated with actual CD4+ T cell 
percentages or log-transformed CD4+ T cell percentages were simply regarded as “CD4+ T cell-
associated.” The list of gene-by-leukocyte population associations is provided in Supplementary Table 7.  
For each leukocyte population for each gene set, the following values are provided: # of genes in 
reference = number of genes in the reference gene set annotated to that module or pathway, # of genes in 
 
gene set of interest = number of genes in the gene set annotated to that module or pathway, p (one-sided 
Fisher's Exact Test), and FDR. 
 
Supplementary Table 9: Wilcoxon rank sum test statistics comparing expression levels of protection 
signature genes in the RhCMV/TB and BCG+RhCMV/TB groups from Study 1. This table provides 
the results of one-sided Wilcoxon rank-sum tests comparing the expression levels of genes from the 
protection signature in the RhCMV/TB group (n=6) to the BCG + RhCMV/TB group (n=7) from Study 1.  
For each gene, the following values are given: p (one-sided Wilcoxon) = p-value from one-sided 
Wilcoxon rank sum test comparing pre-challenge expression levels for RM in the Study 1 
"BCG+RhCMV/TB" vaccine group to RM in the Study 1 "RhCMV/TB" vaccine group and FDR = 
Benjamini-Hochberg-adjusted p (one-sided Wilcoxon). 
The NIHMS has received the file 'Suppl. Tables NMed-A88164-REVISED.xlsx' as 
supplementary data. The file will not appear in this PDF Receipt, but it will be linked to the 
web version of your manuscript. 
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